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Abstract
Regulatory agencies warn about acute kidney injury (AKI) risk following sodium-glucose
cotransporter-2 (SGLT2) inhibitor use. This population-based retrospective cohort study
in Ontario, Canada quantified the 90-day AKI risk in older adults who were newly
dispensed either SGLT2 inhibitors or dipeptidyl peptidase-4 (DPP4) inhibitors in an
outpatient setting between 2015 and 2017. Risk ratios (RR) were obtained using modified
Poisson regression and risk differences using binomial regression. Relative to new use of
a DPP4 inhibitor, initiation of an SGLT2 inhibitor was associated with a lower 90-day
risk of a hospital encounter with AKI: 216 events in 19,611 patients (1.10%) versus 388
events in 19,483 patients (1.99%); weighted RR 0.79 (95% conﬁdence interval 0.64 to
0.98). In routine care of older adults, new SGLT2 inhibitor use was associated with lower
risk of AKI. Together with previous evidence, these findings suggest that regulatory
warnings about AKI risk with SGLT2 inhibitors may be unwarranted.

Keywords
Administrative data, retrospective cohort study, SGLT2 inhibitors, type 2 diabetes, acute
kidney injury
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Summary for Lay Audience
The number of drugs used to treat patients with diabetes has grown significantly.
Sodium-glucose costransporter-2 (SGLT2) inhibitors are an example of a new class of
diabetes medications that help lower blood sugar by promoting its loss in the urine.
Despite the ability of SGLT2 inhibitors to lower blood sugar, the US Food and Drug
Administration (FDA) and Health Canada have issued safety warnings of the link
between SGLT2 inhibitors and kidney injury. These warnings were made based on
individual case reports and case series. We used health administrative databases to
examine elderly patients with diabetes who were prescribed SGLT2 inhibitors and we
examined kidney injury. We found that, in the first 90 days after being prescribed an
SGLT2 inhibitor, patients had lower risk of developing kidney injury, compared to a
similar group of people taking different diabetes medications. We suggest that the safety
warnings and concerns about SGLT2 inhibitors and the risk of kidney injury might be
revisited.
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Chapter 1

1

Introduction

Sodium-glucose cotransporter-2 (SGLT2) inhibitors (e.g. canagliflozin, empagliflozin
and dapagliflozin) are a class of diabetes medications used to treat type 2 disease.
Although only newly available in Ontario since 2015 (1,2), their popularity is growing: in
2016, an estimated 2 million prescriptions for SGLT2 inhibitors were filled in Canada
alone (3). In addition to effectively lowering blood glucose levels, SGLT2 inhibitors are
only one of two new diabetes therapy drug classes with evidence of cardiovascular risk
reduction in patients with diabetes (4–7).
SGLT2 inhibitors have however been linked with adverse outcomes. In October 2015 and
June 2016 Health Canada and the United States Food and Drug Administration (FDA)
issued safety warnings about the risk of acute kidney injury (AKI) after initiation of
canagliflozin and dapagliflozin, based on case reports and case series (summarized in
Appendix A) (8,9). These safety warnings led to changes in the drug product monographs
to include information about the risk of AKI shortly after initiation.
There is a plausible mechanism for SGLT2 inhibitor-induced AKI. By interfering with
the co-uptake of glucose and sodium in the proximal nephron, SGLT2 inhibitors can
increase sodium delivery to the distal nephron, which can result in afferent arteriole
vasoconstriction and an associated reduction in estimated glomerular filtration rate
(eGFR) (10–14). Even so, recent clinical trials and population-based studies suggest
either no increase or a decrease in AKI risk after SGLT2 inhibitor initiation (4–7,10,15–
17).
We conducted a population-based cohort study of older adults with diabetes newly
dispensed an SGLT2 inhibitor or a dipeptidyl peptidase-4 (DPP4) inhibitor (a comparator
drug also used to manage diabetes) in an outpatient setting. We conducted this study to
better understand the association between SGLT2 inhibitor use and the 90-day risk of a
hospital encounter (emergency department (ED) visit or hospital admission) for AKI in
routine clinical practice.
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Chapter 2

2

Literature Review

2.1 Diabetes burden and SGLT2 inhibitor prescribing
According to the Canadian Chronic Disease Surveillance System, approximately 3
million Canadians were living with diagnosed diabetes in 2014 (18). Patients with
diabetes are at risk of a number of complications including cardiovascular disease, endstage renal disease (ESRD) and lower-limb amputations (19), and they face increased
mortality (20,21). Patients with diabetes also incur high health care costs. (Rosella et al.
showed that patients with diabetes cost the Canadian healthcare system about $16,000,
compared with people without diabetes costing the healthcare system $6,000, over an
eight-year period (22)).
Over the last several years, there have been a number of drugs developed to reduce blood
sugars and diabetes related complications. SGLT2 inhibitors including canagliflozin,
empagliflozin and dapagliflozin have been available on the Ontario Drug Benefits
Formulary since 2015 and 2016 (2). Standard daily drug doses for each of these drugs are
listed in Appendix B. These drugs are also available as combination pills with other oral
hypoglycemic medications (2). In 2016, an estimated 2 million prescriptions for SGLT2
inhibitors were filled in Canada alone, as well as 4.4 million prescriptions in the United
States (3,23).

2.2 Mechanism of SGLT2 inhibitor glucose lowering
SGLT2 inhibitors inhibit sodium-glucose cotransporters, located in the proximal
convoluted tubule of the kidney nephron, from reabsorbing glucose into the bloodstream
(24). Inhibition of sodium-glucose cotransporters causes higher urinary concentrations of
glucose, and can lower the concentration of serum glucose (25).
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2.3 SGLT2 inhibitors and the kidneys
Acute kidney injury (AKI) is a serious condition characterized by a sudden increase in
the concentration of serum creatinine (SCr) and a decrease in urine output (26). AKI
ranges in severity. According to the 2012 Kidney Disease: Improving Global Outcomes
(KDIGO) Clinical Practice Guideline, AKI can be diagnosed if any of the following
criteria is met: (i) an increase in SCr ≥ 0.3 mg/dl (≥ 26.5 μmol/l within 48 hours; or (ii) an
increase in SCr to ≥ 1.5 times a baseline measurement within 7 days; or (iii) a reduction
in urine output < 0.5 ml/kg/h for 6 hours (27).
According to the International Society of Nephrology, there are more than 13 million
cases of AKI ever year (28). The presence of type 2 diabetes increases the risk of AKI
(29,30). In addition, elderly patients are more likely to present with AKI (31,32), AKI is
associated with a higher risk of all-cause mortality and ESRD, and higher healthcare
costs (31,33,34). Therefore efforts to lower the risk of AKI in type 2 diabetes is vital.
The mechanism of AKI following the use of an SGLT2 inhibitor is not entirely
understood with a number of mechanisms proposed (35–37). Heerspink et al. suggest that
by interfering with the co-uptake of glucose and sodium in the proximal nephron, SGLT2
inhibitors can increase sodium delivery to the distal nephron, which can result in afferent
arteriole vasoconstriction and an associated reduction in eGFR (10–14).
There are several proposed mechanisms to explain a potential protective effect of SGLT2
inhibitors and the risk of acute and chronic renal adverse events. Through their
mechanism of action of decreasing glucose reabsorption at the kidneys, SGLT2 inhibitors
may suppress renal swelling (38,39), inflammation (40) and may also affect energy
metabolism in renal cells to improve efficiency (41). Since SGLT2 inhibitors also
facilitate lower sodium reabsorption at the kidneys, these drugs can have beneficial
effects that potentially may involve restoring tubuloglomerular feedback, oxygen
consumption changes and improving renal anemia (42). Lastly, the beneficial systemic
effects of SGLT2 inhibitors, such as reductions in body weight, blood pressure and
insulin levels, can lead to renal protection. A reduction in body weight can lower
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albuminuria and reduced insulin levels can lower the risk of hyperinsulinemia which can
damage the kidneys (42,43).

2.4 Search strategy and quality assessment of prior studies
We conducted a literature review to identify prior studies that examined the association
between SGLT2 inhibitor use and AKI. Both MEDLINE (1946 to July 2019) and
EMBASE (1947 to July 2019) were searched, along with the first 5 pages of Google, in
order to review the grey literature. For both databases, the final search strategy consisted
of keywords such as acute kidney injury, acute kidney failure and sodium glucose
cotransporter 2 inhibitor. Full information about the literature search strategies can be
found in Appendix C.
Inclusion and exclusion criteria were developed a priori. Studies were included if they
met the following criteria: (i) full-text English article, (ii) randomized controlled trial
(RCT) or cohort study, (iii) more than 1,000 patients, (iv) reported AKI as an outcome
(AKI could be assessed in any manner such as diagnostic codes for an adverse event or
actual SCr laboratory values). Studies were not included if they (i) were cross-sectional,
commentaries, editorials, letters, methodology papers, or narrative review articles, (ii)
had a sample size that was less than 1,000 patients, and (iii) did not report the outcome of
AKI.

2.5 Summary of previous literature
Seven studies were identified as meeting our inclusion criteria. Four of these studies were
RCTs and three were cohort studies. Overall, studies showed no risk or a reduction in
both the acute and chronic renal adverse events amongst SGLT2 inhibitor users
(summarized in Table 1). Our assessment of study quality using the Modified Downs and
Black quality checklist (44) determined that three were of fair quality (16,16,18), one was
of good quality (25), and three were of excellent quality (27,28,28).
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2.6 SGLT2 inhibitors and acute kidney injury
Two RCTs included in this literature review specifically intended to primarily assess
efficacy in terms of renal outcomes associated with SGLT2 inhibitor use: CANVAS-R
and the CREDENCE trial (5,7). The CREDENCE trial, published earlier this year, had a
primary renal outcome and found that a safety endpoint of AKI was non-significantly
lower in the arm randomized to canagliflozin compared with placebo (hazard ratio (HR)
0.85 (95% CI 0.64-1.13)). The primary composite renal outcome of doubling of SCr,
ESRD, renal death, and cardiovascular death occurred less frequently among patients
randomized to canagliflozin versus placebo (HR 0.70 (95% CI 0.59-0.82)).
Every study included in the literature review consistently showed that there was no
increased risk of AKI amongst SGLT2 inhibitor users. However, all four of the major
RCTs included in our review showed an initial drop in eGFR within 3 months of the
initiation of an SGLT2 inhibitor (4–7,10). This drop in eGFR suggests a hemodynamic
effect similar to the one observed following the initiation of angiotensin-converting–
enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) (45,46). This initial
drop was reported to be reversible.
Additionally, case reports identified through the FDA adverse event reporting system
database identified a signal of AKI following SGLT2 inhibitor use (47).
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Table 1. Literature review of 7 published studies describing adverse renal events associated with SGLT2 inhibitor use compared with
other classes of hypoglycemic medications or hypoglycemic medication non-use for the treatment of hyperglycemia

Author

Study Description

Results

Study
Limitations

Study
Procedure/Exposure
Time

Quality
Scoreb

Randomized Controlled Trials
Zinman
et al.,
2015 (4)

- The EMPA-REG
OUTCOME trial consisted
of 7,020 patients at 590
sites in 42 countries
- Adult patients ≥18 years
of age with type 2 diabetes
and established
cardiovascular disease were
randomized to receive
placebo, 10 mg of
empagliflozin or 25 mg of
empagliflozin

- 2,333 patients received
placebo and 4,687 patients
received empagliflozin
(mean age 63 years in both
groups)
- Early worsening of eGFR
by about 3 ml/min/1.73m2
within the first 12 weeks,
but sustained function over
time (10)a
- The percentage of
patients with AKI was
lower in the empagliflozin
groups compared to
placebo
- Doubling of the SCr
level occurred less among
empagliflozin users [HR
0.56 (95% CI 0.39–0.79)]
(10)a
- The risk of renal-

- Renal findings
may not be
generalizable to
patients without
established
cardiovascular
disease
- Kidney
endpoints were
exploratory (AKI
was not one of
the primary
outcomes of
interest)

- Patients underwent a 2
week, open-label, placebo
run-in period
- Patients either took
empagliflozin or placebo
once daily for a median
duration of treatment of 2.6
years
- Additional follow-up visit
30 days after the end of
treatment
- The median observation
time was 3.1 years

28
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Neal et
al., 2017
(5)

- The CANVAS program
consisted of integrated data
from two trials (CANVAS
& CANVAS-R) involving
10,142 participants from
667 centers in 30 countries
- Adult patients ≥30 years
of age with type 2 diabetes
and high cardiovascular
risk were randomized to
receive placebo, 100 mg
canagliflozin or 300 mg of
canagliflozin in CANVAS;
placebo, 100 mg of
canagliflozin with an
option to increase to 300
mg of canagliflozin starting
at week 13 in CANVAS-R

Wiviott
et al.,
2018 (6)

- The DECLARE–TIMI 58
trial consisted of 17,160
participants at 882 sites in
33 countries
- Adult patients ≥40 years
of age with type 2 diabetes
and who had or were at risk

replacement therapy was
lower amongst
empagliflozin users [HR
0.45 (95% CI 0.21-0.97)]
(10)a
- 4,347 patients received
placebo and 5,795 patients
received canagliflozin
(mean age of 63 years in
both groups)
- No higher risk of AKI
following canagliflozin
use versus placebo
- The composite outcome
of a sustained 40%
reduction in the estimated
glomerular filtration rate,
the need for renalreplacement therapy, or
death from renal causes
occurred less frequently in
patients receiving
canagliflozin [HR 0.60
(95% CI 0.47 to 0.77)]
- 8,578 patients received
placebo and 8,582 patients
received dapagliflozin
(mean age 64 years in both
groups)
- AKI occurred less
frequently in the

- Moderate
number of events
for important
outcomes
- AKI was not
one of the
primary
outcomes of
interest

- Patients underwent a 2week, single-blind, placebo
run-in period
- The median follow-up
was 126.1 weeks
-71.4% of CANVAS-R
patients in the canagliflozin
treatment group had the
dose increased to 300mg
- The urinary ACR was
measured every 26 weeks
in CANVAS-R and at
week 12 and annually
thereafter in CANVAS
- SCr with eGFR
measurements were
performed at least every 26
weeks in both trials

27

- Renal findings
may not be
generalizable to
patients not at
risk for
atherosclerotic
cardiovascular

- Patients underwent a 4to-8-week, single-blind
run-in period during which
they received placebo, and
blood and urine testing was
performed
- Patients returned for

28
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for atherosclerotic
cardiovascular disease were
randomized to receive 10
mg of dapagliflozin or
matching placebo

Perkovic
et al.,
2019 (7)

- The CREDENCE trial
consisted of 4,401
participants with type 2
diabetes and albuminuric
chronic kidney disease
- Adult patients ≥30 years
of age were randomized to
receive 100 mg of
canagliflozin or matching
placebo

dapagliflozin group
compared with placebo
[HR 0.69 (95% CI 0.55 to
0.87)]
- The renal composite
outcome of a sustained
decrease of 40% or more
in estimated glomerular
filtration rate (eGFR), new
ESRD, or death from renal
or cardiovascular causes
occurred less frequently in
dapagliflozin users [HR
0.76 (95% CI 0.67 to
0.87)]
- 2,199 patients received
placebo and 2,202 patients
received canagliflozin
(mean age 63 years in both
groups)
- Initial decline in eGFR
within the first 3 months
of initiation of
canagliflozin
- There was no difference
in the risk of AKI between
groups [HR 0.85 (95% CI
0.64 to 1.13)]
- The primary composite
outcome of ESRD
(dialysis, transplantation,

disease
- AKI was not
one of the
primary
outcomes of
interest

follow-up every 6 months
- Patients were contacted
by telephone every 3
months between in-person
visits
- Median follow-up time
was 4.2 years

- Findings about
AKI may not be
generalizable to
those without
established
albuminuric
chronic kidney
disease
- Trial was
stopped early
which might have
limited the power
for the AKI
outcome

- Patients underwent a 2week, single-blind, placebo
run-in period
- Patients were required to
be receiving a stable dose
of an ACE inhibitor or
ARB for at least 4 weeks
before randomization
- Patients received 100mg
once daily of canagliflozin
or matching placebo with
the use of randomly
permuted blocks, with
stratification according to
the category of eGFR at
screening

25
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or a sustained eGFR of
<15 ml per minute per
1.73 m2 ), a doubling of the
SCr level, or death from
renal or cardiovascular
cause occurred less
frequently among
canagliflozin users [HR
0.70 (95% CI 0.59 to
0.82)]

- Follow-up occurred at
weeks 3, 13, and 26 and
then alternated between
telephone calls and inclinic visits at 13-week
intervals
- Median follow-up time of
2.62 years

Population-Based Studies
Nadkarni
et al.,
2017 (15)

- Retrospective cohort
study using data from the
Mount Sinai chronic kidney
disease registry, between
January 2014 and
December 2016, and the
Geisinger Health System
cohort, between January
2013 and February 2017, in
the United States, to
compare SGLT2 inhibitor
users versus nonusers

- Mount Sinai cohort
(mean age 63 years) SGLT2 inhibitor users:
n=372; nonusers: n=372
- Geisinger cohort (mean
age 58 years) - SGLT2
inhibitor users: n=1,207;
nonusers: n=1,207
- In the Mount Sinai
cohort, the adjusted
hazards of AKI KDIGO were
60% lower in SGLT2
inhibitor users compared
to nonusers [adjusted HR
0.40 (95% CI 0.20 to
0.70)]
- In the Geisinger cohort,
the adjusted hazards of
AKI KDIGO was not

- In the Mount
Sinai cohort,
users and
nonusers were
not well matched
on race, HbA1c
levels, thiazide
diuretics, and
metformin use
- Urine ACR
measurements
were missing in
85% of the
Mount Sinai
cohort
- Residual
confounding and
confounding by
indication may

- Only patients with type 2
diabetes and available SCr
measurements were
included
- Exposure was a new
prescription for
canagliflozin,
empagliflozin or
dapagliflozin
- Follow-up time was
similar in SGLT2 inhibitor
users and nonusers (458 vs.
439 days)

16
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Cahn et
al., 2018
(16)

- Retrospective cohort
study using claims data
from Israel to compare
patients initiated on an
SGLT2 inhibitor or DPP4
inhibitor between April
2015 to June 2017

Ueda et
al., 2018
(17)

- Retrospective cohort
study using data from
nationwide health and
administrative registers in
Sweden and Denmark to
compare patients that
newly initiated an SGLT2

different between SGLT2
inhibitor users and
nonusers [adjusted HR
0.60 (95% CI 0.40 to
1.10)]
- SGLT2 inhibitor users:
n=6,418 (mean age 62
years); DPP4 inhibitor
users: n=5,604 (mean age
64 years)
- The risk of AKI [OR
0.47 (95% CI 0.27 to
0.80)] was lower in
patients initiating an
SGLT2 inhibitor versus a
DPP4 inhibitor

- SGLT2 inhibitor users:
n=17,213; GLP1 receptor
agonists: n=17,213 (mean
age 61 years after
matching)
- No increase in the risk of
AKI [HR 0.69 (95%CI

likely be present

- May be
selection bias in
patients who
initiated an
SGLT2 inhibitor
or DPP4 inhibitor
- Since
canagliflozin is
not available in
Israel, only
patients who
initiated
empagliflozin or
dapagliflozin
were included
- Residual
confounding may
be present

- Only dapagliflozin and
empagliflozin are available
in Israel
- The index date was
defined as the first date of
purchase of SGLT2
inhibitor or DPP4 inhibitor
- At least two consecutive
prescriptions within 120
days on the index date was
required for study inclusion
- The first SCr
measurement within 2 to
24 weeks after index was
defined as the follow-up
measurement
- Follow-up time was 24
weeks following the index
date
- The use of
- The date of filling the
canagliflozin was first new prescription was
rare among
considered the index date
SGLT2 inhibitor - Patients were classified as
users
exposed if prescriptions
- Medication
were refilled before the
compliance might estimated end date of the

16

18

11

inhibitor or a GLP1
receptor agonist between
July 2013 to December
2016

0.45 to 1.05)] in SGLT2
inhibitor users compared
to GLP1 receptor agonist
users

bias the results of
this study
towards the null
- The codes for
AKI have not
been validated
which may have
led to outcome
misclassification
- Residual
confounding may
be present

most recent prescription
- Median follow-up time
ranged between 270 and
274 days

Abbreviations: ACE= angiotensin-converting–enzyme, ACR= albumin-to-creatinine ratio, AKI= acute kidney injury, ARB=
angiotensin-receptor blocker, CI= confidence interval, DPP4= dipeptidyl peptidase-4, eGFR = estimated glomerular filtration rate,
ESRD= end-stage renal disease, GLP1= glucagon-like peptide-1, HbA1c= glycated hemoglobin, HR= hazard ratio, KDIGO= kidney
disease improving global outcomes, OR= odds ratio, SCr= serum creatinine, SGLT2= sodium-glucose cotransporter-2
aWanner et al. presented the results of a prespecified secondary objective of the EMPAREG-OUTCOME trial, which was to examine
the effects of empagliflozin on microvascular outcomes.
b We evaluated the quality of studies using the Modified Downs and Black checklist for the assessment of the methodological quality
of both randomized and non-randomized studies. We gave all studies a score from 0 to 27, grouped into the following four quality
levels: excellent (26 to 28), good (20-25), fair (15-19) and poor (14 or less).
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Chapter 3

3

Rationale and Research Questions

3.1 The need for research
Many previous studies exploring the link between SGLT2 inhibitors and AKI have been
RCTs and may not represent routine clinical practice. In the real-world, for example,
patients in routine clinical practice are generally monitored less often and have more
comorbidity than patients in clinical trials (48). There may also be low rates of AKI
among patients well-managed in a trial setting who receive regimented safety monitoring
that is not attainable in real-world clinical practice. This may result in a potential
underestimate of relative and absolute safety, as has been observed with limb amputation
in some studies (17,49). In addition, in the real-world, clinicians are increasingly
educated on appropriate SGLT2 inhibitor use in routine clinical practice which includes
counseling patients not to take the drug during an acute illness (50). We conducted this
study to better understand the association between SGLT2 inhibitor use and the 90-day
risk of a hospital encounter (ED visit or hospital admission) for AKI in routine clinical
practice.

3.2 Research questions and hypothesis
3.2.1 Primary Research Question
Does a group of older adults with diabetes newly dispensed SGLT2 inhibitors compared
with a group of patients newly dispensed DPP4 inhibitors, who have similar indicators of
baseline health, have an altered 90-day risk of a hospital encounter with AKI?
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3.2.2 Secondary Research Questions
1) Does a group of older adults with diabetes newly dispensed SGLT2 inhibitors
compared with a group of patients newly dispensed DPP4 inhibitors, who have
similar indicators of baseline health, have an altered 90-day risk of hospitalization
with AKI?

2) Does a group of older adults with diabetes newly dispensedSGLT2 inhibitors
compared with a group of patients newly dispensed DPP4 inhibitors, who have
similar indicators of baseline health, have an altered 90-day risk of a hospital
encounter with moderate to severe AKI?

3) Does a group of older adults with diabetes newly dispensed SGLT2 inhibitors
compared with a group of patients newly dispensed DPP4 inhibitors, who have
similar indicators of baseline health, have an altered 90-day risk of AKI restricted to
the outpatient setting?

4) Does a group of older adults with diabetes newly dispensed SGLT2 inhibitors
compared with a group of patients dispensed DPP4 inhibitors, who have similar
indicators of baseline health, have an altered 90-day risk of AKI in all settings
(outpatient, emergency room, in-patient hospitalization)?

Regulatory warnings and recent literature are conflicting, as the warnings describe a
higher risk of AKI after SGLT2 inhibitor initiation, but recent literature showed no
difference in risk or lower risk of AKI after SGLT2 inhibitor initiation. Therefore, we are
uncertain of the direction of association between SGLT2 inhibitor initiation and the risk
of AKI.
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Chapter 4

4

Methods

4.1 Study design and setting
We conducted a population-based retrospective cohort study of older adults aged ≥66
years in Ontario between July 1, 2015 and September 30, 2017 using linked healthcare
databases in Ontario, Canada. Ontario has >14 million residents, 17% of whom are aged
65 years or older (51). Ontario residents are covered by publicly-funded, universal health
insurance. The Ontario Health Insurance Plan (OHIP) covers physician and hospital
services for all Ontario residents. Those aged 65 years and older receive prescription drug
coverage through the Ontario Drug Benefit (ODB) program. Dispensation records for
individuals not covered by the ODB program are not available.
Health administrative databases are increasingly being used for population-based studies
(52). Administrative database studies allow investigators to study large samples of
patients for long follow-up periods and examine outcomes in a routine-care setting. In
addition, loss to follow-up is of little concern since emigration from Ontario is less than
0.1% annually (53). We have successfully used these data sources to study associations
between a number of drugs and risk of AKI (54–57).
We conducted this study at ICES, a not-for-profit research institute within Ontario. The
use of data in this project was authorized under section 45 of Ontario’s Personal Health
Information Protection Act, which does not require review by a Research Ethics Board.
We followed reporting guidelines for observational pharmacoepidemiology studies
(Appendix D) (58).
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4.2 Databases
We used nine health administrative databases to ascertain patient information, drug
exposure status, covariate and outcome information. Databases were linked using unique
encoded identifiers and analyzed at ICES. We have used a number of these databases in
previous pharmacoepidemiologic studies (55–57,59–62).
Ontario Drug Benefit (ODB) Database: The ODB database contains prescription claims
data for individuals aged 65 years or older covered through the ODB Program. This
database was used to ascertain SGLT2 inhibitor or DPP4 inhibitor exposure status as well
as baseline drug use prior to the cohort entry date. We also acquired patient residential
status to remove long-term care residents from our cohort.
Registered Persons Database of Ontario (RPDB): We used this database to acquire
information on patient demographics (age and sex), as well as income quintiles (based on
neighborhood average incomes), and residence location (urban or rural).
ICES Physician Database (IPDB): The IPDB contains information about all physicians in
Ontario, including demographics, specialty, and measures of physician activity (billings
and workload data). We used this database to acquire information about the prescribing
physician’s specialty. We also determined the specialty of the physician for the baseline
number of general physician visits, cardiologist, ophthalmologist, endocrinologist and
nephrologist consults.
Canadian Institute for Health Information (CIHI) Discharge Abstract Database (DAD),
National Ambulatory Care Reporting System (NACRS) and Same Day Surgery (SDS)
Database: CIHI-DAD contains patient-level information on hospitalizations in Ontario.
The NACRS database captures information on patient visits to hospital emergency
departments or other community-based ambulatory care clinics. The SDS dataset
contains patient-level data for day surgery institutions in Ontario. Diagnostic codes are
entered into these databases including the International Classification of Diseases, Tenth
Revision (ICD-10) codes. We used these databases to ascertain baseline comorbidities in
the 5 years prior to the cohort entry date, as well as the number of hospitalizations and
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ED visits. We used ICD-10 codes to ascertain our primary outcome of a hospital
encounter with AKI.
Ontario Health Insurance Plan (OHIP) Claims Database: The OHIP Claims Database
contains information on health care providers’ billing claims for inpatient and outpatient
services in Ontario, as well as associated diagnoses. We used this data source to ascertain
whether patients received dialysis in the one year prior to the cohort entry date (exclusion
criteria). We also gathered additional information on baseline comorbidities and
healthcare utilization. Further, we used OHIP billing codes in outcome ascertainment to
collect information about acute dialysis.
Ontario Laboratories Information System (OLIS): OLIS is an electronic repository that
houses laboratory test results beginning in 2007 in hospitals and community laboratories
across the province. Since not all laboratories began submitting their data to OLIS
simultaneously, we identified geographical areas across Ontario where residents would
likely visit a hospital with linked laboratory data (referred to as the laboratory catchment
area). We included only Ontarians that resided within these laboratory catchment areas.
We used information from OLIS to determine baseline SCr measurements, other baseline
laboratory measurements as well as inpatient and outpatient laboratory data for our
outcomes.
Ontario Diabetes Dataset (ODD): The ODD contains all individuals within Ontario with
any type of non-gestational diabetes. We used this data source to determine duration of
diabetes for all individuals in our cohort.

4.3 Patients
We created a cohort of older adults aged ≥66 years in Ontario who were newly dispensed
an SGLT2 inhibitor (canagliflozin, empagliflozin or dapagliflozin) or a DPP4 inhibitor
(saxagliptin, sitagliptin or linagliptin) between July 1, 2015 (the earliest date of SGLT2
inhibitor coverage by ODB) (2) and September 30, 2017. We chose DPP4 inhibitors as
our comparator as they are also a second to third line medication for diabetes (reduces
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concerns of confounding by indication) and unlike SGLT2 inhibitors, have no known risk
of AKI (63,64). The dispensing date of their first eligible prescription during the accrual
period was considered the cohort entry or index date. We limited our cohort to those aged
≥66 years to establish complete medication history and ensure they were not in their first
eligibility year for prescription drug coverage (age 65 years), and to those who fell in
OLIS catchment areas, using previously published methods (65). We included only
Ontarians who resided within these catchment areas to ensure accurate outcome
ascertainment, as not all hospital-based laboratories started contributing to OLIS at the
same time, and to date, not all contribute. In order to accurately ascertain outcomes for
individuals in our cohort, we ensured individuals resided within areas serviced by OLIS,
so that they would be receiving SCr tests in hospitals captured in our data sources. We
assessed eGFR using the Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) equation (66). Patients were included if their corresponding baseline eGFR value
was above 45 mL/min per 1.73 m2 , as SGLT2 inhibitors were contraindicated in Ontario
for patients with a lower eGFR during the study period (67). Lastly, to define new use,
we required that patients be free of the study drugs for at least 180 days prior to the index
date and studied the first such exposure during accrual period.
We excluded: (i) those with a prescription for more than one type of DPP4 inhibitor or
SGLT2 inhibitor on the index date to compare mutually exclusive groups; (ii) those
residing in long-term care since these individuals are inherently different than the general
population in terms of disease and medication management (68); (iii) those discharged
from a hospital in the two days prior to the index date, to ensure new outpatient
prescriptions since patients who initiate treatment in hospital typically fill ongoing
prescriptions on the discharge date or the day after; and (iv) individuals with nonstandard daily drug doses for diabetes treatment to ensure applicability to usual
prescribing (5mg/day to 300mg/day depending on the drug) (Appendix B) (69). Finally,
for patients with multiple eligible prescriptions we restricted to the first eligible one.
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4.4 Baseline characteristics
We assessed baseline comorbidities in the five years prior to the cohort entry date (except
the Charlson comorbidity index which had a 2-year look back period) and medication use
in the 120 days prior to the cohort entry date. Dispensing of other hypoglycemic
medications was examined in the 120 days prior to the cohort entry date, on the cohort
entry date and in the one year to 120 days prior to the cohort entry date. Health care
utilization was assessed in the year prior to the cohort entry date, except for bone mineral
density tests, hearing tests, sputum tests, which were all assessed in the 5 years prior to
the cohort entry date. Additionally, wound swabs were measured in the 7 days prior to
the cohort entry date, and electroencephalography in the 90 days prior to the cohort entry
date. We assessed baseline kidney function using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation (66) and baseline SCr measurements
for the entire cohort, in the one year prior to the cohort entry date. We had no information
about race and assumed all patients to be nonblack for the CKD-EPI equation (<5% of
the Ontario population is of black race) (70). For individuals with laboratory data
available, we also captured serum potassium values, albumin-to-creatinine (ACR) ratio
measurements and glycated hemoglobin (HbA1c) in the one year prior to the cohort entry
date (see Appendix E for all coding definitions).

4.5 Inverse probability of treatment weighting
We used inverse probability of treatment weighting (IPTW) based on propensity scores to
minimize the systematic differences in the measured baseline characteristics of our
SGLT2 and DPP4 groups. By using weights based on propensity scores, we created a
synthetic population where the distribution of baseline characteristics was independent of
their drug exposure status, while retaining data from all included individuals (71).
To do this, we estimated the propensity scores using a multivariable logistic regression
model with 97 baseline characteristics (selected because of their association with both the
outcome of AKI and type of oral hypoglycemic agent dispensed (see Appendix F for
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variables included in the propensity score). We then used weights to estimate the average
treatment effect in the treated (ATT), where SGLT2 inhibitors were considered the
treated population (72). Patients in the reference group were weighted as [propensity
score/(1 - propensity score)], while patients in the exposed group received a weight of 1.
This allowed us to create a weighted pseudo-sample of patients in the reference group
with the same distribution of measured covariates as the exposure group (71,73,74).
The 97 variables used to estimate propensity scores were complete, except for prescriber
specialty (<10% missing), rural residence (<0.5% missing) and neighbourhood income
quintile (<0.5% missing). Prior to weighting, we classified missing prescriber specialty as
a ‘missing’ category, missing rural status as non-rural, and imputed the third income
quintile for missing income status. Emigration from Ontario is less than 0.1% per year
and was the only reason for lost follow-up (53).

4.6 Outcomes
4.6.1 Primary outcome
Our primary outcome was a hospital encounter (hospitalization or ED presentation) with
AKI, defined by 2012 KDIGO thresholds: ≥50% increase in SCr concentration over
baseline, or an absolute increase of at least 27 µmol/L (0.3 mg/dL) or receipt of dialysis
for AKI (27). The baseline value was the most recent outpatient SCr value within the past
year. We compared this baseline value to the highest hospital-based SCr value in the 90
days following cohort entry. We chose a 90-day follow-up period based on prior evidence
showing that SGLT2 inhibitors lead to an eGFR decline soon after drug initiation (7,10).

4.6.2 Secondary outcomes
As secondary outcomes, we assessed hospital admission with AKI, and hospital
encounter with moderate to severe AKI (SCr increase meeting KDIGO threshold of stage
2 or more AKI; defined in Appendix G) (27). We also examined evidence of AKI in the
outpatient setting, and AKI in any setting (outpatient, in-hospital or ED).
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4.7 Additional analyses
We conducted six additional analyses to assess the robustness of our results.
To assess the possibility of surveillance bias, we examined the proportion of patients in
both groups who had at least one outpatient SCr measurement during the follow-up
period.
To complement analyses examining increases in SCr as a binary outcome, we assessed
absolute and relative changes in SCr measurements after drug initiation.
We completed sub-group analyses to understand potential SGLT2 inhibitor-associated
risks in vulnerable segments of the population who are at higher risk of AKI (75–81). We
examined the association between SGLT2 inhibitor use (versus DPP4 inhibitor use) and
the primary outcome, stratified by presence or absence of four characteristics: (1)
baseline eGFR <60 mL/min per 1.73 m2 , (2) concurrent ACE inhibitor or ARB use, (3)
concurrent diuretic use, and (4) age >80 years (Appendix H).
We performed a survival analysis of the primary outcome within 365 days of follow-up,
censoring on death.
We evaluated the 90-day risk of a hospital encounter with bowel obstruction, as a
negative control outcome which was not expected to be associated with SGLT2 inhibitor
or DPP4 inhibitor use.
We performed an E-value analysis in order to assess how robust our association was to
potential unmeasured confounding (82).

4.8 Statistical analyses
We conducted all analyses using SAS version 9.4 (SAS Institute, Cary, NC, USA). DPP4
inhibitors were the referent group for all analyses. Two-tailed P values less than 0.05
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were considered statistically significant for all outcomes. We present the 95% confidence
intervals (CIs) for all primary outcome estimates, which correspond to a level of
significance of 0.05. In addition to statistical significance, clinical significance was also
considered by including input from practicing physicians.
We compared baseline characteristics between those newly dispensed SGLT2 inhibitors
and DPP4 inhibitors using standardized differences, for which a threshold of ≥10% was
considered meaningful (83). The standardized difference was chosen because it is less
sensitive to sample size, in comparison to hypothesis testing (84), and has been
previously used to compare the distribution of baseline characteristics between treatment
groups (85–87).
To estimate weighted risk ratios (RRs) and 95% CIs, we used a modified Poisson
regression by specifying a generalized linear model assuming a Poisson distribution and
log link function with a repeated statement to obtain robust error variances (88). The
modified Poisson regression provides estimates of RR for dichotomous outcomes. The
clinical interpretation of the RR has more value, when compared with the odds ratio (OR)
(88–90). The modified Poisson regression was selected over other models that estimate
the RR directly in order to avoid the common convergence issues encountered when
using a log-binomial regression model and the conservative results prod uced from
Poisson regression (91–97). To estimate weighted risk differences (RDs) between the
groups and 95% CIs, we used binomial regression with an identity link function (92).
To evaluate the effect of SGLT2 inhibitor use on AKI for specific subgroups, we first
included an interaction term between our exposure and subgroup indicator in our
modified Poisson model. This resulted in an interaction P value, which allowed us to
assess departure from risk-ratio multiplicativity (98).
To assess absolute and relative changes in SCr measurements after drug initiation,
weighted mean differences and 95% CIs were obtained using an ordinary least squares
linear regression model with an identity link function. This model was used because we
were interested in comparing SCr measurements as a continuous variable (99).
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To examine the primary outcome within 365 days of follow-up, we used Cause specific
weighted Cox proportional hazards regression, censoring on the competing risk of death
to estimate weighted HRs (99). The corresponding 95% CI was obtained using a
bootstrap estimator (100). In addition, the proportional hazards assumption was tested by
including time dependent covariates in the model and the assumption was not violated.
To further explore the competing risk of death, we estimated the subdistributions hazards
using a Fine and Gray model treating death as a competing risk (101). However, the
applicability of this model when using IPTW has not yet been fully explored in the
literature (102). As such, we included this analysis only to explore the potential impact of
death in the estimation of AKI within 365 days in SGLT2 users compared to DPP4 users.
In order to assess how robust our association was to potential unmeasured confounding,
we performed an E-value analysis to obtain the minimum strength of association that a
combination of unmeasured confounders would need to have with both the exposure and
outcome to negate the observed results (82,103). The E-value is a measure of a given
association’s robustness to potential unmeasured confounders (82). We produced a
plotted curve using an online E-value calculator that provides the e-value for the point
estimate of our primary outcome and for the CI of the primary outcome (104). However,
in general with the E-value analysis, caution is warranted when interpreting the E-values
as these values are a simplification of the context around the study (i.e. the exposureoutcome association in question, how well all currently measured confounders were
accounted for, etc.) (105).
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Chapter 5

5

Results

5.1 Cohort characteristics
5.1.1 Unweighted cohort
After exclusions, we identified 19,611 patients newly dispensed an SGLT2 inhibitor and
19,483 patients newly dispensed a DPP4 inhibitor between July 1, 2015 and September
30, 2017 (see Figure 1 for cohort assembly). Baseline characteristics pre- and postweighting are presented in Table 2. The mean age of the unweighted cohort was 71 years
for SGLT2 inhibitor users and 74 years for DPP4 inhibitor users. 48% of DPP4 inhibitor
users and 40% of SGLT2 inhibitor users were women. A total of 48% of SGLT2 inhibitor
users were dispensed canagliflozin, 37% empagliflozin and 15% dapagliflozin. The
median (25th , 75th percentile) doses were 100 (100-300) mg/day for canagliflozin, 10 (1010) mg/day for empagliflozin, and 10 (5-10) mg/day for dapagliflozin.
Prior to weighting, SGLT2 inhibitor users were more likely to be younger (71 vs. 74
years), more likely to receive their prescription from an endocrinologist (19.3% vs.
7.6%), were less likely to have a prior AKI diagnosis (1.8% vs. 3.6%), were more likely
to be taking ACE inhibitors (36.5% vs. 31.5%) and were more likely to have HbA1c
levels checked (96.9% vs. 94.4%) than DPP4 users (Table 2). Socioeconomic status was
missing for 33 (0.2%) of SGLT2 inhibitor users and 18 (0.1%) of DPP4 inhibitor users.
Residential information was not available for 33 (0.2%) SGLT2 inhibitor users and 18
(0.1%) DPP4 inhibitor users. In addition, prescriber information was unavailable for
1,261 (6.5%) of DPP4 inhibitor users and 1,091 (5.6%) of SGLT2 inhibitor users.

5.1.2 Weighted cohort
The mean age was 71 years and 40% were women for both SGLT2 inhibitor users and
DPP4 inhibitor users. Baseline SCr was measured a median of 28 days (IQR 9-89) prior
for SGLT2 inhibitor users and 23 (8-81) days for DPP4 inhibitor users. After weighting,
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groups remained imbalanced on eGFR categories, but where considered as a continuous
variable, there was no statistical or clinically meaningful difference between groups.
Overall 17% of the cohort had a weighted baseline eGFR between 45 and 60 mL/min per
1.73 m2 .
Over 120 measured baseline characteristics were similar between SGLT2 inhibitor users
and DPP4 inhibitor users, including diabetes parameters, diabetes medications and
healthcare utilization measures. Prescriber information was missing for 1,131 (5.7%)
DPP4 inhibitor users and 1,091 (5.6%) of SGLT2 inhibitor users. General practitioners
were the most frequent prescribers (65%) for both SGLT2 inhibitors and DPP4 inhibitors
(Table 2).

5.2 Main analysis
5.2.1 Primary outcome
Relative to new DPP4 inhibitor use, new SGLT2 inhibitor use was associated with a
lower 90-day risk of a hospital encounter with AKI: 216 events in 19,611 patients
(1.10%) versus 388 events in 19,483 patients (1.99%); weighted RR 0.79 (95% CI 0.64 to
0.98), p-value 0.04; weighted RD -0.29% (95% CI -0.57% to -0.01%) (Table 3).

5.2.1 Secondary outcomes
SGLT2 inhibitor use was associated with a lower 90-day risk of hospitalization with
AKI: 149 events in 19,611 patients (0.76%) versus 291 events in 19,483 patients
(1.49%); weighted RR 0.73 (95% CI 0.56 to 0.95), p-value 0.02; weighted RD -0.28%
(95% CI -0.53% to -0.03%) (Table 2). The point estimate for the risk of hospital
encounter with moderate to severe AKI following SGLT2 inhibitor use compared with
DPP4 inhibitor use was similar to the primary outcome analysis. However with fewer
events, there was less precision in the estimate and the between-group difference was not
significantly different: 44 events in 19,611 patients (0.22%) versus 74 events in 19,483
patients (0.38%) events; weighted RR 0.81 (95% CI 0.49 to 1.33), p-value 0.40. There
was no significant difference in the risk of AKI in an outpatient setting: 573 events in
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19,611 patients (2.92%) versus 609 events in 19,483 patients (3.13%); weighted RR 1.13
(95% CI 0.95 to 1.33), p-value 0.16 and AKI in all settings: 716 in 19,611 patients
(3.65%) versus 837 events in 19,483 patients (4.30%) events; weighted RR 1.06 (95% CI
0.92 to 1.22), p-value 0.42 (Table 3).

5.3 Additional analyses
Over a 90-day follow-up, SGLT2 inhibitor users were more likely to have at least one
SCr measurement in the outpatient setting compared with DPP4 inhibitor users [10,619
(54.2%) of SGLT2 inhibitor users and 9,602 (49.3%) of DPP4 inhibitor users, p-value <
0.01 (Appendix I)].
The change in SCr concentration in follow-up compared to the baseline value for SGLT2
inhibitor users and DPP4 inhibitor users is presented in Appendices J and K. SGLT2
inhibitor users, compared with DPP4 inhibitor users, had a slightly greater change in SCr
concentration from baseline during follow-up, however the change was not clinically
significant [weighted mean between-group difference in absolute terms was 1 µmol/L
(95% CI 0.3 to 1.7), p-value < 0.01; and as a percentage was 1.3% (95% CI 0.4 to 2.1), pvalue < 0.01].
Baseline eGFR, ACE inhibitor or ARB use, diuretic use, and older age did not
significantly modify the association between SGLT2 inhibitor (versus DPP4 inhibitor)
use and the risk of AKI (P values for interaction ranged from 0.28-0.83) (Figure 2).
Over a 365-day follow-up period, SGLT2 inhibitor use was associated with a lower risk
of hospital encounter with AKI: 2,666 events in 19,611 patients (13.6%) versus 3,712
events in 19,483 patients (19.1%), 172 versus 208 weighted events per 1,000 personyears, respectively; HR 0.83 (95% CI 0.78 to 0.89) (Appendix L). A similar result was
observed when death was treated as a competing risk.
A significant difference in hospital encounters with bowel obstruction between SGLT2
inhibitor users and DPP4 inhibitor users was neither expected nor observed: 20 events in
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19,611 patients (0.10%) versus 36 events in 19,483 patients (0.18%); weighted RR 1.00
(95% CI 0.49 to 2.06), p-value 1.00 (Appendix M).
The E-values for the relative risk and lower confidence bound for the primary outcome
were 1.83 and 1.14, respectively, indicating the amount of unmeasured confounding that
would be needed to bias the observed association to the null (Appendix N).
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Figure 1. Cohort assembly for patients in the SGLT2 inhibitor user group and the comparator DPP4
inhibitor user group
aESRD defined as evidence of previous dialysis or renal transplant; b To ensure two mutually exclusive
groups; cIndividuals are inherently different than the general population in terms of medication
management; d To ensure new outpatient prescriptions; eTo ensure applicability to usual prescribing
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Table 2. Baseline characteristics of older adults with type 2 diabetes newly dispensed SGLT2 inhibitors (canagliflozin, dapagliflozin
or empagliflozin) and DPP4 inhibitors (saxagliptin, sitagliptin or linagliptin) in Ontario, Canada (2015-2017)

Characteristica

SGLT2 inhibitor type
Canagliflozin
Empagliflozin
Dapagliflozin
DPP4 inhibitor type
Sitagliptin
Linagliptin
Saxagliptin
Demographics
Age, year, mean ± SD
Age, year, median
(IQR)
66-74
75-84
85+
Women
Rural Residenced
Year of cohort entry
2015
2016

Observed data
No. (%) of patients
SGLT2
DPP4
inhibitors
inhibitors
(n = 19,611)
(n = 19,483)

Standardized
Differencec
(%)

Weighted datab
No. (%) of patients
SGLT2
DPP4
inhibitors
inhibitors
(n = 19,611) (n = 19,775)

Standardized
Differencec
(%)

9,404 (48.0)
7,311 (37.3)
2,896 (14.8)
13,086 (67.2)
4,726 (24.3)
1,671 (8.6)
71.4 ± 4.86

74.1 ± 6.3

47

71.4 ± 4.9

71.4 ± 5.0

1

70 (68 to 74)

73 (69 to 78)

43

70 (68 to 74)

70 (68 to 74)

1

15,017 (76.6)
4,249 (21.7)
345 (1.8)
7,903 (40.3)
2,192 (11.2)

11,415 (58.6)
6,586 (33.8)
1,482 (7.6)
9,325 (47.9)
2,088 (10.7)

39
27
28
15
2

15,017 (76.6)
4,249 (21.7)
345 (1.8)
7,903 (40.3)
2,192 (11.2)

15,224 (77.0)
4,153 (21.0)
398 (2.0)
8,104 (41.0)
2,423 (12.3)

1
2
1
1
3

3,571 (18.2)
8,060 (41.1)

4,260 (21.9)
9,153 (47.0)

9
12

3,571 (18.2)
8,060 (41.1)

3,187 (16.1)
8,940 (45.2)

6
8

29

2017
7,980 (40.7)
Neighbourhood income quintilee
1 (low)
4,350 (22.2)
2
4236 (21.6)
3
4,011 (20.5)
4
3,679 (18.8)
5 (high)
3,302 (16.8)
Local health integration network (LHIN)
1
36 (0.2)
2
1,765 (9.0)
3
254 (1.3)
4
21 (0.1)
5
1,864 (9.5)
6
2,121 (10.8)
7
1,774 (9.0)
8
3,441 (17.5)
9
4,897 (25.0)
10
967 (4.9)
11
290 (1.5)
12
996 (5.1)
13
825 (4.2)
14
360 (1.8)
Prescriber Speciality
Cardiologist
413 (2.1)
Endocrinologist
3,786 (19.3)
General practitioner
12,798 (65.3)
Internist
1,139 (5.8)
Nephrologist
217 (1.1)
Other
167 (0.9)
Missing
1,091 (5.6)
Comorbidities in prior 5 years

6,070 (31.2)

20

7,980 (40.7)

7,647 (38.7)

4

4,566 (23.4)
4,390 (22.5)
3,953 (20.3)
3,513 (18.0)
3,043 (15.6)

3
2
0
2
3

4, 350 (22.2)
4,236 (21.6)
4,044 (20.6)
3,679 (18.8)
3,302 (16.8)

4,397 (22.2)
4,328 (21.9)
4,047 (20.5)
3,683 (18.6)
3,321 (16.8)

0
1
0
1
0

15 (0.1)
1,890 (9.7)
179 (0.9)
19 (0.1)
1,954 (10.0)
2,696 (13.8)
1,852 (9.5)
3,332 (17.1)
4,218 (21.6)
751 (3.9)
345 (1.8)
813 (4.2)
984 (5.1)
435 (2.2)

3
2
4
0
2
9
2
1
8
5
2
4
4
3

36 (0.2)
1765 (9.0)
254 (1.3)
21 (0.1)
1,864 (9.5)
2,121 (10.8)
1,774 (9.0)
3,441 (17.5)
4,897 (25.0)
967 (4.9)
290 (1.5)
996 (5.1)
825 (4.2)
360 (1.8)

29 (0.1)
1,869 (9.4)
262 (1.3)
23 (0.1)
1,797 (9.1)
2,162 (10.9)
1,873 (9.5)
3,167 (16.0)
5,058 (25.6)
1,019 (5.2)
278 (1.4)
1,00 (5.1)
874 (4.4)
363 (1.8)

3
1
0
0
1
0
2
4
1
1
1
0
1
0

108 (0.6)
1,475 (7.6)
15,685 (80.5)
540 (2.8)
97 (0.5)
317 (1.6)
1,261 (6.5)

13
35
35
15
7
6
4

413 (2.1)
3,786 (19.3)
12,798 (65.3)
1,139 (5.8)
217 (1.1)
167 (0.9)
1,091 (5.6)

506 (2.6)
3,574 (18.1)
12,927 (65.4)
1,232 (6.2)
234 (1.2)
171 (0.9)
1,131 (5.7)

3
3
0
2
1
0
0
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Duration of diabetes,
years, mean ± SD
Duration of diabetes,
years, median (IQR)
<1 year
1-4 years
5-9 years
10-19 years
20-29 years
Diabetic retinopathy
Diabetic neuropathy
Hypoglycemia
Hyperglycemic
emergency
Prior acute kidney
injury
Prior acute urinary
retention
Chronic obstructive
pulmonary disease
Chronic lung disease
Cancer
Stroke
Atrial Fibrillation
Ventricular arrhythmia
Coronary artery bypass
graft surgery
Percutaneous coronary
intervention
Pacemaker

13.8 ± 6.9

12.0 ± 7.2

25

13.8 ± 6.9

13.8 ± 7.1

1

14 (9 to 19)

12 (6 to 17)

25

14 (9 to 19)

14 (8 to 20)

1

699 (3.6)
1,707 (8.7)
3,611 (18.4)
9,319 (47.5)
4,275 (21.8)
168 (0.9)
231 (1.2)
115 (0.6)

1,357 (7.0)
2,435 (12.5)
4,303 (22.1)
8,114 (41.6)
3,274 (16.8)
140 (0.7)
257 (1.3)
185 (0.9)

15
12
9
12
13
2
1
3

699 (3.6)
1,707 (8.7)
3,611 (18.4)
9,319 (47.5)
4,275 (21.8)
168 (0.9)
231 (1.2)
115 (0.6)

696 (3.5)
1,767 (8.9)
3,733 (18.9)
8,984 (45.4)
4,595 (23.2)
172 (0.9)
223 (1.1)
127 (0.6)

1
1
1
4
3
0
1
0

47 (0.2)

82 (0.4)

4

47 (0.2)

75 (0.4)

4

351 (1.8)

702 (3.6)

11

351 (1.8)

395 (2.0)

1

252 (1.3)

452 (2.3)

8

252 (1.3)

237 (1.2)

1

396 (2.0)

490 (2.5)

3

396 (2.0)

453 (2.3)

2

3,885 (19.8)
5,586 (28.5)
270 (1.4)
717 (3.7)
61 (0.3)

3,976 (20.4)
5,987 (30.7)
556 (2.9)
930 (4.8)
76 (0.4)

1
5
10
5
2

3,885 (19.8)
5,586 (28.5)
270 (1.4)
717 (3.7)
61 (0.3)

4,049 (20.5)
5,579 (28.2)
256 (1.3)
702 (3.5)
66 (0.3)

2
1
1
1
0

513 (2.6)

372 (1.9)

5

513 (2.6)

514 (2.6)

0

1,051 (5.4)

777 (4.0)

7

1,051 (5.4)

1,010 (5.1)

1

543 (2.8)

561 (2.9)

1

543 (2.8)

518 (2.6)

1
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Congestive heart
1,649 (8.4)
failure
Transplant - hepatic
8 (0.0)
Chronic liver disease
947 (4.8)
Coronary artery disease
6,665 (34.0)
Peripheral vascular
202 (1.0)
disease
Hypertension
15,302 (78.0)
Hypotension
176 (0.9)
Hyponatremia
202 (1.0)
Influenza vaccination
14,066 (71.7)
Prior respiratory
12,540 (63.9)
infection
Prior skin & soft tissue
19,428 (99.1)
infection
Prior other infections
6,343 (32.3)
Hyperkalemia
85 (0.4)
Urinary incontinence
195 (1.0)
Urinary retention
252 (1.3)
Prior urinary tract
578 (2.9)
infections
Charlson comorbidity indexf
Mean ± SD
0.3 ± 0.9
Median (IQR)
0 (0 to 0)
0
16,722 (85.3)
1
943 (4.8)
2
862 (4.4)
3
1,084 (5.5)
Medicationsg
ACE inhibitors
7,155 (36.5)
ARB
4,754 (24.2)

1,876 (9.6)

4

1,649 (8.4)

1,674 (8.5)

0

7 (0.0)
978 (5.0)
5,985 (30.7)

4
1
7

8 (0.0)
947 (4.8)
6,665 (34.0)

9 (0.0)
916 (4.6)
6,669 (33.7)

0
1
1

218 (1.1)

1

202 (1.0)

188 (1.0)

0

13,528 (69.4)
297 (1.5)
393 (2.0)
13,393 (68.7)

20
6
8
7

15,302 (78.0)
176 (0.9)
202 (1.0)
14,066 (71.7)

15,477 (78.3)
157 (0.8)
203 (1.0)
13,912 (70.4)

1
1
0
3

12,169 (62.5)

3

12,540 (63.9)

12,559 (63.5)

1

19,112 (98.1)

9

19,428 (99.1)

19,602 (99.1)

0

6,299 (32.3)
131 (0.7)
209 (1.1)
452 (2.3)

0
4
1
8

6,343 (32.3)
85 (0.4)
195 (1.0)
252 (1.3)

6,391 (32.3)
86 (0.4)
177 (0.9)
237 (1.2)

0
0
1
1

1,015 (5.2)

12

578 (2.9)

661 (3.3)

2

0.5 ± 1.2
0 (0 to 0)
15,676 (80.5)
1,147 (5.9)
1,044 (5.4)
1,616 (8.3)

14
13
13
5
5
11

0.3 ± 0.9
0 (0 to 0)
16,722 (85.3)
943 (4.8)
862 (4.4)
1,084 (5.5)

0.3 ± 1.0
0 (0 to 0)
16,998 (86.0)
852 (4.3)
862 (4.4)
1,063 (5.4)

1
1
2
2
0
0

6,128 (31.5)
4,095 (21.0)

11
8

7,155 (36.5)
4,754 (24.2)

7,271 (36.8)
4,856 (24.6)

1
1
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ACE or ARB
11,796 (60.1)
ACE and ARB
113 (0.6)
Acetylsalicyclic acid h
436 (2.2)
Beta blockers
6,427 (32.8)
Calcium channel
6,167 (31.4)
blockers
NSAIDsi
2,076 (10.6)
Statins
14,887 (75.9)
Proton pump inhibitors
4,264 (21.7)
Picosalax
169 (0.9)
Cephalosporins
823 (4.2)
Lithium
23 (0.1)
Amoxicillin
1,518 (7.7)
Ciprofloxacin
434 (2.2)
Norfloxacin
51 (0.3)
Nitrofurantoin
377 (1.9)
Sulfamethoxazole &
159 (0.8)
trimethoprim
Overactive bladder
329 (1.7)
medications
Loop diuretics
1,289 (6.6)
Potassium sparing
610 (3.1)
diuretics
Thiazide diuretics
2,700 (13.8)
Any diuretic type
4,240 (21.6)
Number of unique diuretic types
0
15,371 (78.4)
1
3,892 (19.8)
2
337 (1.7)
3
11 (0.1)
Number of unique drug names

10,124 (52.0)
99 (0.5)
395 (2.0)
5,679 (29.1)

16
1
1
8

11,796 (60.1)
113 (0.6)
436 (2.2)
6,427 (32.8)

12,008 (60.7)
120 (0.6)
497 (2.5)
6,442 (32.6)

1
0
2
0

5,540 (28.4)

7

6,167 (31.4)

6,205 (31.4)

0

1,684 (8.6)
12,257 (62.9)
4,137 (21.2)
169 (0.9)
849 (4.4)
28 (0.1)
1,468 (7.5)
561 (2.9)
74 (0.4)
566 (2.9)

7
28
1
0
1
0
1
4
2
7

2,076 (10.6)
14,887 (75.9)
4,264 (21.7)
169 (0.9)
823 (4.2)
23 (0.1)
1,518 (7.7)
434 (2.2)
51 (0.3)
377 (1.9)

2,144 (10.8)
15,031 (76.0)
4,352 (22.0)
158 (0.8)
870 (4.4)
30 (0.2)
1,717 (8.7)
494 (2.5)
74 (0.4)
501 (2.5)

1
0
1
1
1
3
4
2
2
4

220 (1.1)

3

159 (0.8)

203 (1.0)

2

352 (1.8)

1

329 (1.7)

345 (1.7)

0

1,376 (7.1)

2

1,289 (6.6)

1,352 (6.8)

1

635 (3.3)

1

610 (3.1)

602 (3.0)

1

2,608 (13.4)
4,231 (21.7)

1
0

2,700 (13.8)
4,240 (21.6)

2,874 (14.5)
4,460 (22.6)

2
2

15,252 (78.3)
3,858 (19.8)
358 (1.8)
15 (0.1)

0
0
1
0

15,371 (78.4)
3,892 (19.8)
337 (1.7)
11 (0.1)

15,315 (77.4)
4,110 (20.8)
332 (1.7)
18 (0.1)

2
2
0
0
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Mean ± SD
7.87 ± 4.07
6.91 ± 4.43
23
7.87 ± 4.07
Median (IQR)
7 (5 to 10)
7 (4 to 9)
24
7 (5 to 10)
0-4 drug names
3,654 (18.6)
5,916 (30.4)
28
3,654 (18.6)
5-9 drug names
10,179 (51.9)
8,698 (44.6)
15
10,179 (51.9)
10-15 drug names
4,924 (25.1)
4,113 (21.1)
10
4,924 (25.1)
15-19 drug names
625 (3.2)
554 (2.8)
2
625 (3.2)
20+ drug names
229 (1.2)
202 (1.0)
2
229 (1.2)
Hypoglycemic medications dispensed in prior 120 days
Insulin
5,229 (26.7)
2,508 (12.9)
35
5,229 (26.7)
Acarbose
366 (1.9)
141 (0.7)
11
366 (1.9)
Gliclazide
6,606 (33.7)
4,385 (22.5)
25
6,606 (33.7)
Glyburide
719 (3.7)
1,004 (5.2)
7
719 (3.7)
Metformin
15,765 (80.4)
12,738 (65.4)
34
15,765 (80.4)
Repaglinide
6 (0.0)
10 (0.1)
4
6 (0.0)
Rosiglitazone maleate
13 (0.1)
16 (0.1)
0
13 (0.1)
Pioglitazine
100 (0.5)
104 (0.5)
0
100 (0.5)
Hypoglycemic medications dispensed on the cohort entry date
Insulin
1,153 (5.9)
803 (4.1)
8
1,153 (5.9)
Acarbose
122 (0.6)
105 (0.5)
1
122 (0.6)
Gliclazide
2,077 (10.6)
2,176 (11.2)
2
2,077 (10.6)
Glyburide
172 (0.9)
292 (1.5)
6
172 (0.9)
Metformin
5,589 (28.5)
5,422 (27.8)
2
5,589 (28.5)
Pioglitazine
26 (0.1)
9 (0.0)
4
26 (0.1)
Hypoglycemic medications dispensed in the 1 year to 120 days before the cohort entry date
Insulin
5,664 (28.9)
2,877 (14.8)
35
5,664 (28.9)
Acarbose
445 (2.3)
217 (1.1)
9
445 (2.3)
Gliclazide
7,457 (38.0)
5,459 (28.0)
21
7,457 (38.0)
Glyburide
1,003 (5.1)
1,419 (7.3)
9
1,003 (5.1)
Metformin
16,698 (85.1)
14,552 (74.7)
26
16,698 (85.1)
Repaglinide
7 (0.0)
20 (0.1)
4
7 (0.0)
Rosiglitazone maleate
19 (0.1)
22 (0.1)
0
19 (0.1)

8 ± 4.28
8 (5 to 10)
3,837 (19.4)
9,633 (48.7)
5,286 (26.7)
747 (3.8)
273 (1.4)

3
3
2
6
4
3
2

5,582 (28.2)
447 (2.3)
6,870 (34.7)
740 (3.7)
15,837 (80.1)
23 (0.1)
12 (0.1)
108 (0.5)

3
3
2
0
1
4
0
0

1,110 (5.6)
126 (0.6)
1,946 (9.8)
159 (0.8)
5,439 (27.5)
7 (0.0)

1
0
3
1
2
4

5,997 (30.3)
522 (2.6)
7,672 (38.8)
1,025 (5.2)
16,695 (84.4)
28 (0.1)
15 (0.1)

3
2
2
0
2
4
0

34

Pioglitazine
125 (0.6)
Healthcare use in the past 1 year
Number of any hospitalizations
Mean ± SD
0.12 ± 0.45
Median (IQR)
0 (0 to 0)
0 visits
17,821 (90.9)
1 visit
1,364 (7.0)
2 visits
314 (1.6)
3+ visits
112 (0.6)
Number of any ED visits
Mean ± SD
0.5 ± 1.24
Median (IQR)
0 (0 to 1)
0 visits
14,234 (72.6)
1 visit
3,292 (16.8)
2 visits
1,136 (5.8)
3+ visits
949 (4.8)
GP/FP visits
Mean ± SD
8.22 ± 6.72
Median (IQR)
7 (4 to 10)
0 visits
460 (2.3)
1-2 visits
1,702 (8.7)
3-4 visits
3,462 (17.7)
5-6 visits
3,824 (19.5)
7-8 visits
3,101 (15.8)
9-10 visits
2,222 (11.3)
11+ visits
4,840 (24.7)
Cardiologist visits
Mean ± SD
1.12 ± 2.36
Median (IQR)
0 (0 to 1)
0 visits
11,273 (57.5)
1 visit
3,882 (19.8)

141 (0.7)

1

125 (0.6)

148 (0.7)

1

0.22 ± 0.65
0 (0 to 0)
16,618 (85.3)
1,977 (10.1)
562 (2.9)
326 (1.7)

18
18
17
11
9
10

0.12 ± 0.45
0 (0 to 0)
17,821 (90.9)
1,364 (7.0)
314 (1.6)
112 (0.6)

0.12 ± 0.44
0 (0 to 0)
18,001 (91.0)
1,378 (7.0)
289 (1.5)
107 (0.5)

0
1
0
0
1
1

0.69 ± 1.57
0 (0 to 1)
12,840 (65.9)
3,596 (18.5)
1,527 (7.8)
1,520 (7.8)

13
16
15
4
8
12

0.5 ± 1.24
0 (0 to 1)
14,234 (72.6)
3,292 (16.8)
1,136 (5.8)
949 (4.8)

0.52 ± 1.12
0 (0 to 1)
14,009 (70.8)
3,487 (17.6)
1,256 (6.4)
1,023 (5.2)

2
2
4
2
3
2

9.37 ± 9.93
7 (4 to 11)
493 (2.5)
1,788 (9.2)
3,256 (16.7)
3,629 (18.6)
2,853 (14.6)
1,988 (10.2)
5,476 (28.1)

14
5
1
2
3
2
3
4
8

8.22 ± 6.72
7 (4 to 10)
460 (2.3)
1,702 (8.7)
3,462 (17.7)
3,824 (19.5)
3,101 (15.8)
2,222 (11.3)
4,840 (24.7)

8.12 ± 6.79
7 (4 to 10)
597 (3.0)
1,707 (8.6)
3,457 (17.5)
4,090 (20.7)
3,076 (15.6)
2,033 (10.3)
4,814 (24.3)

1
1
4
0
1
3
1
3
1

1.25 ± 2.72
0 (0 to 1)
11,042 (56.7)
3,875 (19.9)

5
2
2
0

1.12 ± 2.36
0 (0 to 1)
11,273 (57.5)
3,882 (19.8)

1.12 ± 2.26
0 (0 to 1)
11,397 (57.6)
3,859 (19.5)

0
0
0
1
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2 visits
3+ visits
Opthamologist visits
Mean ± SD
Median (IQR)
0 visits
1 visit
2 visits
3+ visits
Endocrinologist visits
Mean ± SD
Median (IQR)
0 visits
1 visit
2 visits
3+ visits
Nephrologist visits
Mean ± SD
Median (IQR)
0 visits
1 visit
2 visits
3+ visits
Diabetes management
Diabetes incentive
Diabetes management
by a specialist
Diabetes management
by a specialist team
Cholesterol tests
Proteinuria

1,782 (9.1)
2,674 (13.6)

1,701 (8.7)
2,865 (14.7)

1
3

1,782 (9.1)
2,674 (13.6)

1,723 (8.7)
2,795 (14.1)

1
1

1.02 ± 2.24
0 (0 to 1)
12,927 (65.9)
2,828 (14.4)
1,386 (7.1)
2,470 (12.6)

0.95 ± 2.14
0 (0 to 1)
13,196 (67.7)
2,627 (13.5)
1,354 (6.9)
2,306 (11.8)

3
4
4
3
1
2

1.02 ± 2.24
0 (0 to 1)
12,927 (65.9)
2,828 (14.4)
1,386 (7.1)
2,470 (12.6)

1.03 ± 2.27
0 (0 to 1)
13,015 (65.8)
2,814 (14.2)
1,399 (7.1)
2,547 (12.9)

0
1
0
1
0
1

0.6 ± 1.31
0 (0 to 0)
14,809 (75.5)
1,422 (7.3)
1,485 (7.6)
1,895 (9.7)

0.34 ± 1.21
0 (0 to 0)
16,879 (86.6)
957 (4.9)
764 (3.9)
883 (4.5)

21
29
29
10
16
20

0.6 ± 1.31
0 (0 to 0)
14,809 (75.5)
1,422 (7.3)
1,485 (7.6)
1,895 (9.7)

0.59 ± 1.37
0 (0 to 0)
15,214 (76.9)
1,402 (7.1)
1,301 (6.6)
1,858 (9.4)

1
1
3
1
4
1

0.11 ± 0.67
0 (0 to 0)
18,607 (94.9)
501 (2.6)
286 (1.5)
217 (1.1)
11,451 (58.4)
6,855 (35.0)

0.14 ± 1.12
0 (0 to 0)
18,249 (93.7)
624 (3.2)
333 (1.7)
277 (1.4)
10,080 (51.7)
5,782 (29.7)

3
5
5
4
2
3
13
11

0.11 ± 0.67
0 (0 to 0)
18,607 (94.9)
501 (2.6)
286 (1.5)
217 (1.1)
11,451 (58.4)
6,855 (35.0)

0.11 ± 0.57
0 (0 to 0)
18,676 (94.4)
498 (2.5)
350 (1.8)
250 (1.3)
11,805 (59.7)
7,072 (35.8)

0
0
2
1
2
2
3
2

964 (4.9)

289 (1.5)

19

964 (4.9)

925 (4.7)

1

487 (2.5)

112 (0.6)

15

487 (2.5)

447 (2.3)

1

17,740 (90.5)
10,453 (53.3)

16,929 (86.9)
10,905 (56.0)

11
5

17,740 (90.5)
10,453 (53.3)

17,897 (90.5)
10,624 (53.7)

0
1
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SCr tests
Glucose tests
HbA1c tests
DVT/PE
Bone mineral density
test
Hearing test
Sputum
Wound swab
Holter monitoring
Cardiac stress test
Coronary
revascularization
Electrocardiography
Pulmonary function
test
At-home physician
service
Urinalysis
Cystoscopy
Transurethral resection
of the prostate
Carotid ultrasound
Cardiac catheterization
Coronary angiogram
Electroencephalograph
y
Chest x-ray
Echocardiography
Prostate-specific
antigen test

19,026 (97.0)
17,881 (91.2)
18,996 (96.9)
21 (0.1)

18,519 (95.1)
17,288 (88.7)
18,401 (94.4)
48 (0.2)

10
8
12
3

19,026 (97.0)
17,881 (91.2)
18,996 (96.9)
21 (0.1)

19,180 (97.0)
17,948 (90.8)
19,152 (96.8)
22 (0.1)

0
1
0
0

1,201 (6.1)

1,357 (7.0)

4

1,201 (6.1)

1,211 (6.1)

0

866 (4.4)
35 (0.2)
14 (0.1)
1,546 (7.9)
3,124 (15.9)

792 (4.1)
52 (0.3)
18 (0.1)
1,605 (8.2)
2,519 (12.9)

1
2
0
1
9

866 (4.4)
35 (0.2)
14 (0.1)
1,546 (7.9)
3,124 (15.9)

814 (4.1)
54 (0.3)
17 (0.1)
1,576 (8.0)
3,064 (15.5)

1
2
0
0
1

382 (1.9)

292 (1.5)

3

382 (1.9)

338 (1.7)

2

9,239 (47.1)

9,809 (50.3)

6

9,239 (47.1)

9,251 (46.8)

1

2,244 (11.4)

2,051 (10.5)

3

2,244 (11.4)

2,156 (10.9)

2

252 (1.3)

481 (2.5)

9

252 (1.3)

237 (1.2)

1

10,684 (54.5)
612 (3.1)

11,202 (57.5)
778 (4.0)

6
5

10,684 (54.5)
612 (3.1)

10,864 (54.9)
600 (3.0)

1
1

71 (0.4)

81 (0.4)

0

71 (0.4)

53 (0.3)

2

901 (4.6)
661 (3.4)
648 (3.3)

994 (5.1)
503 (2.6)
494 (2.5)

2
5
5

901 (4.6)
661 (3.4)
648 (3.3)

942 (4.8)
587 (3.0)
575 (2.9)

1
2
2

51 (0.3)

138 (0.7)

6

51 (0.3)

50 (0.3)

0

4,899 (25.0)
4,377 (22.3)

5,929 (30.4)
4,262 (21.9)

12
1

4,899 (25.0)
4,377 (22.3)

4,964 (25.1)
4,387 (22.2)

0
0

1,124 (5.7)

845 (4.3)

6

1,124 (5.7)

1,109 (5.6)

0
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Cervical cancer
641 (3.3)
531 (2.7)
screening
Laboratory testsj
Baseline eGFRk , ml/min/1.73m2
Mean ± SD
76.7 ± 13.9
72.9 ± 15.6
Median (IQR)
78 (66 to 88)
74 (59 to 87)
>60 ml/min/1.73m2
16,786 (85.6)
14,405 (73.9)
45-60 ml/min/1.73m2
2,825 (14.4)
5,078 (26.1)
Time from most recent SCr test to cohort entry date
Mean ± SD
61.9 ± 75.6
63.8 ± 83.6
Median (IQR)
28 (9 to 89)
24 (8 to 88)
Baseline SCr, µmol/L
Mean ± SD
79.7 ± 18.1
81.2 ± 20.2
Median (IQR)
78 (66 to 91)
79 (66 to 94)
Baseline potassium, mEq/L
Potassium data
5,556 (28.3)
7,072 (36.3)
available
Mean ± SD
4.5 ± 0.5
4.4 ± 0.5
Median (IQR)
5 (4 to 5)
4 (4 to 5)
Time from most recent ACR test to cohort entry date
Mean ± SD
67.8 ± 90.5
61.4 ± 93.9
Median (IQR)
20 (0 to 106)
10 (0 to 91)
Baseline ACR categories, mg/mmol
ACR data available
14,637 (74.6)
12,381 (63.5)
Undetected
9,424 (48.1)
7,903 (40.6)
3-30
4,263 (21.7)
3,729 (19.1)
>30
950 (4.8)
749 (3.8)
Most recent glycated hemoglobin level, %
Glycated hemoglobin
6,516 (33.2)
8,071 (41.4)
value available
Mean ± SD
7.8 ± 1.2
7.7 ± 1.3

4

641 (3.3)

614 (3.1)

1

26
24
29
29

76.7 ± 13.9
78 (66 to 88)
16,786 (85.6)
2,825 (14.4)

76.7 ± 15.6
80 (64 to 90)
16,009 (81.0)
3,766 (19.0)

0
0
12l
12l

2
6

61.9 ± 75.6
28 (9 to 89)

59.7 ± 78.5
23 (8 to 81)

3
3

8
6

79.7 ± 18.1
78 (66 to 91)

79.7 ± 20.3
77 (65 to 92)

0
1

17

5,556 (28.3)

6,110 (30.9)

6

13
11

4.5 ± 0.5
5 (4 to 5)

4.5 ± 0.4
5 (4 to 5)

7
5

7
19

67.8 ± 90.5
20 (0 to 106)

65.2 ± 93.1
16 (0 to 101)

3
3

24
15
6
5

14,637 (74.6)
9,424 (48.1)
4,263 (21.7)
950 (4.8)

14,240 (72.0)
9,129 (46.2)
4,288 (21.7)
823 (4.2)

6
4
0
3

17

6,516 (33.2)

7,288 (36.9)

8

12

7.8 ± 1.2

7.8 ± 1.2

2
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Median (IQR)
8 (7 to 8)
7 (7 to 8)
16
8 (7 to 8)
8 (7 to 8)
3
<6
89 (1.4)
224 (2.8)
7
89 (1.4)
129 (1.8)
3
6-<6.5
392 (6.0)
686 (8.5)
9
392 (6.0)
468 (6.4)
3
6.5-<7.0
1,018 (15.6)
1,500 (18.6)
10
1,018 (15.6)
1,175 (16.1)
3
7.0-<7.5
1,334 (20.5)
1,688 (20.9)
7
1,334 (20.5)
1,483 (20.3)
3
≥7.5
3,683 (56.5)
3,973 (49.2)
4
3,683 (56.5)
4,032 (55.3)
4
KFREm data, %
2-year KFRE data
14,637 (74.6)
12,381 (63.5)
24
14,637 (74.6) 14,240 (72.0)
6
available
<5%
14,637 (100)
12,381 (100)
1
14,638 (100) 14,240 (100)
6
5-year KFRE data
14,637 (74.6)
12,381 (63.5)
24
14,637 (74.6) 14,240 (72.0)
6
available
<5%
14,616 (99.9)
12,345 (99.7)
1
14,616 (99.9) 14,200 (99.7)
6
5%+
21 (0.1)
36 (0.3)
1
21 (0.1)
40 (0.3)
3
Abbreviations: ACE= angiotensin-converting–enzyme, ACR= albumin-to-creatinine ratio, ARB= angiotensin-receptor blocker,
DPP4= dipeptidyl peptidase-4, DVT/PE= deep vein thrombosis and pulmonary embolism, ED= emergency department, eGFR =
estimated glomerular filtration, GP/FP= general practice/family practice, HbA1c= glycated hemoglobin, IQR= interquartile range,
KFRE= kidney failure risk equation, NSAID= nonsteroidal anti-inflammatory drug, SCr= serum creatinine, SD= standard deviation,
SGLT2= sodium-glucose cotransporter-2
aUnless otherwise specified, baseline characteristics were assessed on the date the patient filled their prescription: the cohort entry
date.
b Weighted using inverse probability of treatment weighting based on propensity scores, using weights to estimate the average
treatment effect in the treated. Patients in the reference group were weighted as [propensity score/(1 - propensity score)]. This method
produces a weighted pseudo-sample of patients in the reference group with the same distribution of measured covariates as the
exposure group (71,73,74).
cThe difference between the groups divided by the pooled SD; a value greater than 10% is interpreted as a meaningful difference (83).
d Rural residence was defined as a population < 10,000 people. Residential information was not available for 33 (0.2%) SGLT2
inhibitor users and 18 (0.1%) DPP4 inhibitor users in the unweighted cohort. Missing values in the unweighted cohort were reclassified into the “Not rural” category during weighting.
eIncome was categorized into fifths of average neighborhood income on the cohort entry date. Socioeconomic status was missing for
33 (0.2%) of SGLT2 inhibitor users and 18 (0.1%) of DPP4 inhibitor users.
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comorbidity index (106,107) was calculated using five years of hospitalization data. “No hospitalizations” received a score
of 0. A higher score indicates a higher risk of one-year mortality associated with comorbidities.
gMedication use was examined in the 120-day period before the cohort entry date (the Ontario Drug Benefit program dispenses a
maximum 100-day supply.
h Only included dispensed acetylsalicyclic acid use and does not account for over-the-counter acetylsalicyclic acid use.
iExcludes acetylsalicylic acid and does not account for over-the-counter NSAID use.
jMost recent laboratory test values in the 1-to-365–day period before the cohort entry date.
k eGFR was calculated using the Chronic Kidney Disease (CKD)–Epidemiology (EPI) equation: 141 × min([serum creatinine
concentration in μmol/L/88.4]/ĸ, 1)α × max([serum creatinine concentration in μmol/L/88.4]/ĸ, 1)-1.209 × 0.993Age × 1.018 [if
female] × 1.159 [if African-American]; ĸ=0.7 if female and 0.9 if male; α=-0.329 if female and -0.411 if male; min=the minimum of
serum creatinine concentration/ĸ or 1; max=the maximum of serum creatinine concentration/ĸ or 1. Information on race was not
available in our data sources and all patients were assumed not to be of African-Canadian race; African-Canadians represented less
than 5% of the population of Ontario in 2006.
lAlthough the groups were still imbalanced on eGFR categories after weighting, there was no statistical or clinically meaningful
difference when baseline eGFR was assessed as a continuous variable.
m KFRE is based on a prediction model for progression to kidney failure (108). The equation includes age, sex, eGFR and albuminuria.
A higher percentage indicates a greater 2- and 5-year chance of developing treated end-stage kidney disease.
f Charlson
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Table 3. 90-day primary and secondary outcomes of prescription SGLT2 inhibitor new users compared with DPP4 inhibitor new users

Weightedb

Observed
No. events (%)
SGLT2
inhibitors
(n=19,611)

DPP4
inhibitors
(n=19,483)

No. events (%)
SGLT2
inhibitors
(n=19,611)

DPP4
inhibitors
(n=19,775)

Risk difference, %
(95% CI)

Risk ratio
(95% CI)

Pvalue

Primary outcome
Hospital encounter
275
-0.29%
0.79
with acute kidney
216 (1.10%) 388 (1.99%) 216 (1.10%)
0.04
(1.39%)
(-0.57%
to
-0.01%)
(0.64
to 0.98)
injuryc
Secondary outcomes
Hospitalization with
206
-0.28%
0.73
149 (0.76%) 291 (1.49%) 149 (0.76%)
0.02
acute kidney injury
(1.04%)
(-0.53% to -0.03%)
(0.56 to 0.95)
Hospital encounter
with moderate to
-0.05%
0.81
44 (0.22%)
74 (0.38%)
44 (0.22%)
55 (0.28%)
0.40
severe acute kidney
(-0.18% to 0.08%)
(0.49 to 1.33)
injuryd
Acute kidney injury
1.13
513
0.33%
restricted to outpatient 573 (2.92%) 609 (3.13%) 573 (2.92%)
0.16
(0.95 to 1.33)
(2.60%)
(-0.12% to 0.77%)
setting
Acute kidney injury
681
0.21%
1.06
716 (3.65%) 837 (4.30%) 716 (3.65%)
0.42
in all settings
(3.44%)
(-0.28% to 0.70%)
(0.92 to 1.22)
Abbreviations: CI= confidence interval, DPP4= dipeptidyl peptidase-4, SGLT2= sodium-glucose cotransporter-2
aReference group: DPP4 inhibitor users.
b Weighted using inverse probability of treatment weighting based on propensity scores, using weights to estimate the average t reatment effect in the
treated.
cBased on hospital presentation (emergency department or hospitalization) assessed using the Ontario Laboratories Information System serum
creatinine values. This was defined by the 2012 KDIGO thresholds: compared with baseline, a serum creatinine increase ≥ 50% or an absolute
increase of at least 27 µmol/L (0.3 mg/dL) (27).
d Defined according to KDIGO staging thresholds of stages 2 and 3 combined (27).
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Figure 2. Association between SGLT2 inhibitor new use (canagliflozin, dapagliflozin or
empagliflozin) and the 90-day risk of hospital encounter with AKI examined in
subgroups defined by baseline eGFR, ACEi or ARB use, diuretic use and age
Abbreviations: ACEi= angiotensin-converting-enzyme inhibitor, ARB= angiotensin
receptor blocker, CI= confidence interval, DPP4i= dipeptidyl peptidase-4 inhibitor,
eGFR= estimated glomerular filtration rate, N/A= not applicable, SGLT2i= sodiumglucose cotransporter-2 inhibitor
aDiuretic types included loop diuretics, potassium sparring diuretics and thiazide diuretics
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Chapter 6
6 Discussion
6.1 Summary and interpretation of study results
In this large population-based cohort study of older adults, we did not observe a higher
risk of AKI in new users of SGLT2 inhibitors compared with DPP4 inhibitors in any
analysis. Rather, we observed that new use of an SGLT2 inhibitor was associated with a
lower 90-day risk of a hospital encounter with AKI. Results remained robust when the
follow-up was extended to one year. When four subgroups of higher risk patients were
examined, none showed evidence of a higher 90-day risk of AKI following new SGLT2
inhibitor use compared to DPP4 inhibitor use.
These findings are reassuring for the safety of SGLT2 inhibitors as currently prescribed
in routine care. A likely explanation to this observed protective effect is the, now better
understood, mechanism by which SGLT2 inhibitors have demonstrated several
nephroprotective features akin to ACE inhibitors and ARB initiation (45,46,109),
including a reduction in albuminuria and risk of progressive chronic kidney disease
(110,111). The cardiovascular benefits of SGLT2 inhibitors may also result in renal
benefits, given how dependent the kidney is on cardiac function.
Our demonstration of a 21% lower relative risk of AKI is consistent with three published
observational cohort studies (15–17). Two of these studies also used laboratory data to
define AKI (albeit in relatively smaller sample sizes) and both found a >50% lower AKI
risk following SGLT2 inhibitor use (15,16). The most recent observational study with the
most comparable sample size to this current study found SGLT2 inhibitor use versus
GLP1 receptor agonist use resulted in a 31% reduction in AKI risk, but was not
statistically significant (17).
Some might suggest cohort studies suffer from residual confounding leading to spurious
associations. For example, before weighting patients in this study, newly dispensed
SGLT2 inhibitor users demonstrated less comorbidity and better maintained kidney
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function than DPP4 inhibitor users, which might explain the observed lower risk of AKI
with SGLT2 inhibitors even after weighting. However, our results were very similar to
the findings of large recent RCTs and meta-analyses of RCTs. In the CREDENCE study,
patients with type 2 diabetes and chronic kidney disease, who were randomized to receive
canagliflozin, had a lower non-significant risk of AKI compared with placebo (7). A
recent systematic review and meta-analysis by Neuen et al. of over 38,723 participants
from RCTs demonstrated a similar significant 25% reduction in AKI risk with SGLT2
inhibitor use versus placebo (111). A systematic review and meta-analysis by Toyama et
al, of over 7,000 patients from RCTs demonstrated a 31% reduction in AKI risk with
SGLT2 inhibitor use versus placebo, but was not statistically significant (112). Another
meta-analysis of the three major RCTs demonstrated a 34% statistically significant
relative risk reduction in the likelihood of AKI amongst those randomized to receive
SGLT2 inhibitors versus placebo (113).
The totality of randomized and routine care evidence suggests regulatory warnings and
prescribing references about a higher AKI risk with SGLT2 inhibitors may be
unwarranted and might be reconsidered (1,114).

6.2 Strengths and limitations
Our study has several strengths. It is the largest population-based study to date to assess
the risk of a clinically important complication of SGLT2 inhibitor use among older
adults. It is the first Canadian study to evaluate AKI risk in association with an important
medication that is likely to be used more often in response to recent trials demonstrating
its benefits (4,6,7). We used laboratory values, as opposed to diagnostic codes, to more
specifically capture AKI events associated with SGLT2 inhibitor initiation (115,116). We
selected patients who filled a prescription for a different class of oral hypoglycemic
medications as our comparator group to avoid confounding by indication bias that would
arise if we simply examined SGLT2 inhibitor non-users.
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There are several limitations to our study. Given the observational study design, causality
cannot be inferred. Although we chose an active comparator drug that is also 2 nd or 3rd
line medication for diabetes and we balanced on 97 measured baseline characteristics,
confounding by indication cannot be ruled out. When estimating eGFRs using the CKDEPI equation, we had no information about race and assumed all patients to be non-black
for the CKD-EPI equation (<5% of the Ontario population is of black race) (70). Thus,
eGFR values for black patients may not be estimated accurately. In addition, we cannot
account for whether strategies such as sick day management of diabetes medications (i.e.
stopping SGLT2 inhibitors during acute illness) altered the risk of AKI. Although
residual confounding cannot be eliminated, we attempted to reduce it using IPTW and
balanced patients on over 95 characteristics. We also conducted several additional
sensitivity analyses which supported the main findings. In particular, the magnitude of
the E-value, along with the entire context of this study, suggest the observed association
is unlikely to be explained by unmeasured confounding. Some confounders that could not
be captured in our datasets may be smoking status, body mass index, and oral water
intake which when poor may predispose to volume depletion (30,117–120). However, we
have no reason to believe that these factors would be differentially more prevalent
amongst SGLT2i users compared to DPP4i users.
Additional limitations were that we could only identify prescriptions dispensed by a
pharmacy but had no information about medication use or adherence. We only included
patients aged over 66 years, but our study findings are consistent with studies that
included adults of all ages (16,17). The 2012 KDIGO definition of AKI includes timing
elements for when SCr measurements needed to be taken within (increase in SCr within
48 hours and a baseline measurement presumed to have occurred within the prior 7 days),
which were not considered in the current study outcome definitions (27). The SCr
measurements were done as per routine care and about half of the patients did not have a
SCr measurement during the 90-day follow-up period. While we observed a significant
between-group difference in the likelihood of SCr measurement in follow-up, the
absolute difference was not large and we believe it unlikely to affect the overall results.
Following SGLT2 inhibitor initiation clinicians may be more likely to check SCr,
especially in higher risk patients, compared to our comparator group, which could lead to
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a greater (not lower) risk of SGLT2 inhibitor-associated AKI. Lastly, it is important to
note that the population studied was of lower risk of AKI, largely based on wellpreserved kidney function and minimal or no albuminuria. Extrapolation of the findings
to higher risk patients should be done with caution.

6.3 Implications
In older adults in routine clinical practice, new initiation of an SGLT2 inhibitor compared
with DPP4 inhibitors was associated with a lower 90-day AKI risk. This is reassuring for
prescribers, as SCr expectedly increased following SGLT2 inhibitor initiation, but did not
appear to lead to AKI. Taken together with consistent information from other studies,
regulatory warnings about a higher risk of AKI with SGLT2 inhibitors may be
unwarranted and should be revisited.
Consideration can be given to future trials of SGLT2 inhibitor use in patient settings
where the timing and risk of AKI is both predictable and high, such as in the
perioperative setting. As the uptake of SGLT2 inhibitors expands, we will likely see the
drug used by more patients with advanced chronic kidney disease, where the risk-benefit
balance requires attention. Also, better information on the effects of withholding these
drugs in the context of acute illness or infection warrants attention.
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Appendices
Appendix A. Regulatory warnings on the risk of acute kidney injury with SGLT2
inhibitor use (8,9)
Study Drug
Canagliflozin

Empagliflozin

Dapagliflozin

Summary of Warning
- In October 2015, Health Canada released a summary of the safety
review which reported a risk of acute kidney injury following
canagliflozin use. This review was based on reports of acute kidney injury
both to Health Canada and international reports. In addition, scientific
literature was reviewed at the time and it was noted that the drug’s renal
effects might be a potential problem (8).
- In June 2016, the United States Food and Drug Administration (FDA)
strengthened kidney warnings for canagliflozin based on a search of the
FDA adverse event reporting system identifying 101 patients with
sufficient detail to confirm the diagnosis and show a temporal relationship
with canagliflozin (9).
- No warning about the risk of acute kidney injury following the use of
empagliflozin.
- However, in an FDA briefing document discussing the supplemental
new drug application for empagliflozin using data from the EMPA-REG
OUTCOME trial (released shortly after the warnings were issued for
canagliflozin and dapagliflozin), there was a section stating that the risk
of acute kidney injury with empagliflozin is slightly increased compared
to placebo due to the diuretic activity of the drug leading to an early
hemodynamic effect on renal function. In both the first 30 days and first
90 days following empagliflozin use, the incidence of early renal adverse
events was greater in empagliflozin users (121).
- In October 2015, Health Canada released a summary of the safety
review which reported a risk of acute kidney injury following
dapagliflozin use. This review was based on reports of acute kidney
injury both to Health Canada and international reports. In addition,
scientific literature was reviewed at the time it was noted that the drug’s
renal effects might be a potential problem (8).
- In June 2016, the United States Food and Drug Administration (FDA)
strengthened kidney warnings for dapagliflozin based on a search of the
FDA adverse event reporting system identifying 101 patients with
sufficient detail to confirm the diagnosis and show a temporal relationship
with dapagliflozin (9).
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Appendix B. Standard daily doses of SGLT2 inhibitors and DPP4 inhibitors

Drug
SGLT2 inhibitors
Canagliflozin
Empagliflozin
Dapagliflozin

Standard daily drug doses (mg)
100 or 300
10 or 25
5 or 10

DPP4 inhibitors
Saxagliptin
Sitagliptin
Linagliptin

2.5 or 5
25, 50 or 100
5
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Appendix C. Search strategies for literature review

Database
OVID
Medline

OVID
Embase

Search Terms
Acute Kidney Injury/
((kidney or renal) adj3 (insufficien* or injur* or fail*)).mp.
1 or 2
Sodium-Glucose Transporter 2/
(empagliflozin or dapagliflozin or canagliflozin or invokana
5
or forxiga or jardiance).mp.
6
4 or 5
7
3 and 6
RESULTS 261
Ovid MEDLINE(R) ALL <1946 to July 10, 2019>
1
2
3
4

1
2

acute kidney failure/
((kidney or renal) adj3 (insufficien* or injur* or fail*)).mp.
sodium glucose cotransporter 2/ or sodium glucose
3
cotransporter 2 inhibitor/
(empagliflozin or dapagliflozin or canagliflozin or invokana
4
or forxiga or jardiance).mp.
5
1 or 2
6
3 or 4
7
5 and 6
RESULTS 983
Embase Classic+Embase <1947 to 2019 July 10>
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Appendix D. REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement for
Pharmacoepidemiology (RECORD-PE) (58)

Item
STROBE items
No
Title and abstract
1
(a) Indicate the study’s design with
a commonly used term in the title or
the abstract.
(b) Provide in the abstract an
informative and balanced summary
of what was done
and what was found.

Introduction
Background rationale
2
Explain the scientific background
and rationale for the investigation
being reported.
Objectives
3
State specific objectives, including

RECORD items

RECORD-PE items

1.1: The type of data used
should be specified in the title
or abstract.
When possible, the name of
the databases used should be
included.
1.2: If applicable, the
geographical region and
timeframe within which the
study took place should be
reported in the title or abstract.
1.3: If linkage between
databases was conducted for
the study, this should be
clearly stated in the title or
abstract.

—

—

—

Section

Title &
Abstract

Chapter 1 & 2

—

—

Chapter 3
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any
prespecified hypotheses.
Methods
Study design
4
Present key elements of study
design early in the paper.

Setting
5

Describe the setting, locations, and
relevant dates, including periods of
recruitment, exposure, follow-up,
and data collection.

Participants
6
(a) Cohort study—give the
eligibility criteria, and the sources
and methods of selection of
participants. Describe methods of
follow-up. Case-control study—give
the eligibility criteria, and the
sources and methods of case
ascertainment and control selection.

—

—

4.a: Include details of the specific
study
design (and its features) and report
the
use of multiple designs if used.
4.b: The use of a diagram(s) is
recommended to illustrate key
aspects of
the study design(s), including
exposure, washout, lag and
observation periods, and covariate
definitions as relevant.

Chapter 4

—
Chapter 4

6.1: The methods of study
population selection (such as
codes or algorithms used to
identify participants) should be
listed in detail. If this is not
possible, an explanation
should be provided.
6.2: Any validation studies of

6.1.a: Describe the study entry
criteria and the order in which these
criteria were applied to identify the
study population.
Specify whether only users with a
specific indication were included and
whether patients were allowed to
enter the study population once or if

Chapter 4
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Variables
7

Give the rationale for the choice of
cases and controls. Cross sectional
study—give the eligibility criteria,
and the sources and methods of
selection of participants.
(b) Cohort study—for matched
studies, give matching criteria and
number of exposed and unexposed.
Case-control
study—for matched studies, give
matching criteria and the number of
controls per case.

the codes or algorithms used to multiple entries were permitted. See
select the population should be explanatory document for guidance
referenced. If validation was
related to matched designs.
conducted for this study and
not published elsewhere,
detailed methods and results
should be provided.
6.3: If the study involved
linkage of databases, consider
use of a flow diagram or other
graphical display to
demonstrate the data linkage
process, including the number
of individuals with linked data
at each stage.

Clearly define all outcomes,
exposures,
predictors, potential confounders,
and effect modifiers. Give
diagnostic criteria, if applicable.

7.1: A complete list of codes
and
algorithms used to classify
exposures, outcomes,
confounders,
and effect modifiers should be
provided. If these cannot be
reported, an explanation
should be provided.

7.1.a: Describe how the drug
exposure definition was developed.
7.1.b: Specify the data sources from
which drug exposure information for
Chapter 4
individuals was obtained.
•Codes for
7.1.c: Describe the time window(s)
baseline
during which an individual is
characteristics
considered exposed to the drug(s).
available upon
The rationale for\ selecting a
request
particular time window should be
provided. The extent of potential left
truncation or left censoring should be
specified.

67

7.1.d: Justify how events are
attributed to current, prior, ever, or
cumulative drug exposure.
7.1.e: When examining drug dose
and risk attribution, describe how
current, historical or time on therapy
are considered.
7.1.f: Use of any comparator groups
should be outlined and justified.
7.1.g: Outline the approach used to
handle individuals with more than
one relevant drug exposure during
the study period.
Data sources/measurement
8
For each variable of interest, give
sources of data and details of
methods of assessment
(measurement). Describe
comparability of assessment
methods if there is more than one
group.
Bias
9
Describe any efforts to address
potential sources of bias.
Study size
10
Explain how the study size was
arrived at.
Quantitative variables
11
Explain how quantitative variables
were handled in the analyses. If

8.a: Describe the healthcare system
and mechanisms for generating the
drug exposure records. Specify the
care setting in which the drug(s) of
interest was prescribed.

Chapter 4

—

—

Chapter 4
Chapter 6

—

—

Chapter 5:
Figure 1

—

—
Chapter 4
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applicable, describe which
groupings were chosen, and why.
Statistical methods
(a) Describe all statistical methods,
including those used to control for
confounding.
(b) Describe any methods used to
examine subgroups and interactions.
(c) Explain how missing data were
addressed.
(d) Cohort study—if applicable,
explain how loss to follow-up was
addressed.
Case-control study—if applicable,
explain how matching of cases and
controls was addressed. Cross
sectional study—if applicable,
describe analytical methods taking
account of sampling strategy.
(e) Describe any sensitivity
analyses.
Data access and cleaning methods
12
—

—

12.1: Authors should describe
the
extent to which the
investigators
had access to the database
population used to create the
study population.
12.2: Authors should provide
information on the data

12.1.a: Describe the methods used to
evaluate whether the assumptions
have been met.
12.1.b: Describe and justify the use
of multiple designs, design features,
or analytical approaches.

Chapter 4

—

N/A
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cleaning methods used in the
study.
Linkage
12

—

Results
Participants
13
(a) Report the numbers of
individuals at each stage of the
study (eg, numbers potentially
eligible, examined for eligibility,
confirmed eligible, included in the
study, completing follow-up, and
analysed).
(b) Give reasons for nonparticipation at each stage.
(c) Consider use of a flow diagram.
Descriptive
data
14
(a) Give characteristics of study
participants (eg, demographic,
clinical, social) and information on
exposures and potential

12.3: State whether the study
included person level,
institutional level, or other
data linkage across two or
more databases. The methods
of linkage and methods of
linkage quality evaluation
should be provided.

—

13.1: Describe in detail the
selection of the individuals
included in the study (that is,
study population selection)
including filtering based on
data quality, data availability,
and linkage. The selection of
included individuals can be
described in the text or by
means of the study flow
diagram.

—

—

Chapter 4

Chapter 5:
Figure 1

—

Chapter 5:
Table 2
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confounders.
(b) Indicate the number of
participants with missing data for
each variable of interest.
(c) Cohort study—summarise
follow-up time (eg, average and
total amount).
Outcome data
15
Cohort study—report numbers of
outcome events or summary
measures over time.
Case-control study—report numbers
in each exposure category, or
summary measures of exposure.
Cross sectional study—report
numbers of outcome events or
summary measures.
Main results
16
(a) Give unadjusted estimates and, if
applicable, confounder adjusted
estimates and their precision (eg,
95% confidence intervals). Make
clear which confounders were
adjusted for and why they were
included.
(b) Report category boundaries
when continuous variables are
categorised.
(c) If relevant, consider translating
estimates of relative risk into
absolute risk for a meaningful time

—

—

Chapter 5:
Table 3

—

—

Chapter 5:
Table 3
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period.
Other analyses
17
Report other analyses done—eg,
analyses of subgroups and
interactions, and sensitivity
analyses.
Discussion
Key results
18
Summarise key results with
reference to study objectives.
Limitations
19
Discuss limitations of the study,
taking into account sources of
potential bias or imprecision.
Discuss both direction and
magnitude of any potential bias.

Interpretation
20
Give a cautious overall
interpretation of results considering
objectives, limitations, multiplicity
of analyses, results from similar
studies, and other relevant evidence.

—

—

—

—

19.1: Discuss the implications
of using data that were not
created or collected to answer
the specific research
question(s). Include discussion
of misclassification bias,
unmeasured confounding,
missing data, and changing
eligibility over time, as they
pertain to the study being
reported.

19.1.a: Describe the degree to which
the chosen database(s) adequately
captures the drug exposure(s) of
interest.

—

20.a: Discuss the potential for
confounding by indication,
contraindication or disease severity
or selection bias (healthy
adherer/sick stopper) as alternative
explanations for the study findings
when relevant.

Chapter 5:
Figure 2
Appendices IM

Chapter 6

Chapter 6

Chapter 6
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Generalisability
21
Discuss the generalisability
—
(external validity) of the study
results.
Other information
Funding
22
Give the source of funding and the
—
role of
the funders for the present study
and, if applicable, for the original
study on which the present article is
based.
Accessibility of protocol, raw data, and programming code
22
—
22.1: Authors should provide
information on how to access
any supplemental information
such as the study protocol, raw
data, or programming code.

—
Chapter 6

—
N/A

—
N/A
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Appendix E. Coding definitions for demographics, comorbid conditions, healthcare
utilization measures and laboratory measurements

Variable
Demographics
Age
Sex
Location of residence –
Rural status
Socioeconomic status
(neighbourhood income
quintiles)
Local Health Integration
Network (LHIN)
Entry year
Prescribing physician
Comorbidities
Duration of diabetes
Acute kidney injury
Chronic kidney disease

Acute urinary retention
Chronic obstructive
pulmonary disease
Chronic lung disease

Cancer

Database

Codes

RPDB
RPDB
RPDB

RURAL

RPDB

INCQUINT

RPDB

LHIN

IPDB

MAINSPECIALTY

ODD
CIHI-DAD ICD-10: N17
CIHI-DAD ICD-10: E102, E112, E132, E142, I12,
I13, N00, N01, N02, N03, N04, N05, N06,
OHIP
N07, N08, N10, N11, N12, N13, N14,
N15, N16, N17, N18, N19, N20, N21,
N22, N23
OHIP dx: 403, 585
CIHI-DAD ICD-10: R33
CIHI-DAD ICD-10: J41, J43, J44
CIHI-DAD ICD-10: I272, I278, I279, J40, J41, J42,
J43, J44, J45, J47, J60, J61, J62, J63, J64,
CIHIJ65, J66, J67, J68, J701, J703, J704, J708,
NACRS
J709, J82, J84, J92, J941, J949, J953,
J961, J969, J984, J988, J989, J99
OHIP
OHIP dx: 491, 492, 493, 494, 496, 501,
502, 515, 518, 519
OHIP fee: J889, J689
CIHI-DAD ICD-10: 80003, 80006, 80013, 80023,
80033, 80043, 80102, 80103, 80106,
OHIP
80113, 80123, 802, 803, 80413, 80423,
80433, 80443, 80453, 80502, 80503,
80513, 80523, 807, 808, 80903, 80913,
80923, 80933, 80943, 80953, 81103,
81202, 81203, 81213, 81223, 81233,
81243, 81303, 81402, 81403, 81406,
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81413, 81423, 81433, 81443, 81453,
81473, 81503, 81513, 81523, 81533,
81543, 81553, 81603, 81613, 81623,
81703, 81713, 81803, 81903, 82003,
82013, 82102, 82103, 82113, 82203,
82213, 823, 82403, 82413, 82433, 82443,
82453, 82463, 82473, 82503, 82513,
82603, 82612, 82613, 82623, 82632,
82633, 82703, 82803, 82813, 82903,
83003, 83103, 83123, 83143, 83153,
83203, 83223, 83233, 83303, 83313,
83323, 83403, 83503, 83703, 83803,
83813, 83903, 84003, 84013, 84103,
84203, 84303, 84403, 84413, 84423,
84503, 84513, 84603, 84613, 84623,
84703, 84713, 84723, 84733, 84803,
84806, 84813, 849, 85002, 85003, 85012,
85013, 85023, 85032, 85033, 85042,
85043, 851, 852, 85303, 854, 85503,
85603, 85623, 857, 85803, 86003, 86203,
86303, 86403, 86503, 86803, 86933,
87003, 87103, 87202, 87203, 87213,
87223, 87233, 87303, 87403, 87412,
87413, 87422, 87423, 87433, 87443,
87453, 87613, 87703, 87713, 87723,
87733, 87743, 87803, 88003, 88006,
88013, 88023, 88033, 88043, 88103,
88113, 88123, 88133, 88143, 88303,
88323, 88333, 88403, 88503, 88513,
88523, 88533, 88543, 88553, 88583,
88903, 88913, 88943, 88953, 88963,
89003, 89013, 89023, 89103, 89203,
89303, 89333, 89403, 89413, 895, 89603,
89633, 89643, 897, 89803, 89813, 89903,
89913, 90003, 90203, 90403, 90413,
90423, 90433, 90443, 90503, 90513,
90523, 90533,
906, 90703, 90713, 90723, 90803, 90813,
90823, 90833, 90843, 90853, 90903,
91003, 91013, 91023, 91103, 91203,
91243, 91303, 91333, 91403, 91503,
91703, 91803, 91813, 91823, 91833,
91843, 91853, 91903, 92203, 92213,
92303, 92313, 92403, 92503, 92513,
92603, 92613, 92703, 92903, 93103,
93303, 93623, 93643, 93703, 93803,
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Stroke

Atrial fibrillation
Ventricular arrhythmia

Coronary artery bypass
graft surgery
Percutaneous coronary
intervention

93813, 93823, 93903, 93913, 93923, 940,
941, 942, 94303, 944, 945, 94603, 947,
948, 94903, 95003, 95013, 95023, 95033,
95043, 951, 952, 95303, 95393, 95403,
95603, 95613, 95803, 95813, 959, 965,
966, 967, 968, 969, 970, 971, 972, 973,
97403, 97413, 97603, 97613, 97623,
97633, 97643, 980, 982, 98303, 984,
98503, 986, 98703, 98803, 989, 99003,
99103, 993, 994, C00, C01, C02, C03,
C04, C05, C06, C07, C08, C09, C10, C11,
C12, C13, C14, C15, C16, C17, C18, C19,
C20, C21, C22, C23, C24, C25, C26, C30,
C31, C32, C33, C34, C37, C38, C39, C40,
C41, C43, C44, C45, C46, C47, C48, C49,
C50, C51, C52, C53, C54, C55, C56, C57,
C58, C60, C61, C62, C63, C64, C65, C66,
C67, C68, C69, C70, C71, C72, C73, C74,
C75, C76, C77, C78, C79, C80, C81, C82,
C83, C84, C85, C86, C88, C90, C91, C92,
C93, C94, C95, C96, C97, D00, D01, D02,
D03, D04, D05, D06, D07, D09, Z85
OHIP dx: 140, 141, 142, 143, 144, 145,
146, 147, 148, 149, 150, 151, 152, 153,
154, 155, 156, 157, 158, 159, 160, 161,
162, 163, 164,165, 170, 171, 172, 173,
174, 175, 179, 180, 181, 182, 183, 184,
185, 186, 187, 188, 189, 190, 191, 192,
193, 194, 195, 196, 197, 198, 199, 200,
201, 202, 203, 204, 205, 206, 207, 208,
230, 231, 232, 233, 234
CIHI-DAD ICD-10: I62, I630, I631, I632, I633, I634,
I635, I638, I639, I64, H341, I600, I601,
I602, I603, I604, I605, I606, I607, I609,
I61, G450, G451, G452, G453, G458,
G459, H340
CIHI-DAD ICD-10: I48
CIHI-DAD ICD-10: I472, I4900
NACRS
CIHI-DAD CCI: 1IJ76
OHIP fee: R742, R743, E654, E645, E652,
OHIP
E646
CIHI-DAD CCI: 1IJ50, 1IJ57GQ, 1IJ54GQAZ
OHIP fee: Z434, G262, G298
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Pacemaker

Congestive heart failure

Transplant - hepatic

Chronic liver disease

Coronary artery disease

Diabetic retinopathy

Diabetic neuropathy

OHIP
CIHI-DAD CCI: 1HZ37, 1HD53GRJA, 1HD54GRJA,
1HZ53GRNK, 1HZ53GRNL,
CIHI1HZ53GRNM, 1HZ54LANJ, 2HZ07NK
NACRS
2HZ07NL, 2HZ07NM, 1HZ53GRFR,
1HZ53LAFR, 1HZ53SYFR, 1HD55,
OHIP
1HZ09, 1HZ55, 2HZ24, 1Hz53GRNN
OHIP fee: G303, Z433, Z435, Z443, Z444,
Z445, R752, Z412, Z428, E628, G176,
G177, G115
CIHI-DAD ICD-10: I099, I420, I425, I426, I427, I428,
I429, I43, I500, I501, I509, I255, J81
OHIP
CCP: 4961, 4962, 4963, 4964
CCI: 1HP53, 1HP55, 1HZ53GRFR,
1HZ53LAFR, 1HZ53SYFR
OHIP fee: R701, R702, Z429
OHIP dx: 428
CIHI-DAD ICD-10: T86400, T86401, T86402, Z944,
CCI: 1OA85
OHIP
OHIP fee: S294, S295, E765, G254
CIHI-DAD ICD-10: B16, B17, B18, B19, I85, R17,
R18, R160, R162, B942, Z225, E831,
OHIP
E830, K70, K713, K714, K715, K717,
K721, K729, K73, K74, K753, K754,
K758, K759, K76, K77
OHIP dx: 571, 573, 070
OHIP fee: Z551, Z554
CIHI-DAD ICD-10: I20, I21, I22, I23, I24, I25, Z955,
Z958, Z959, R931, T822
OHIP
CCI: 1IJ26, 1IJ27, 1IJ54, 1IJ57, 1IJ50,
1IJ76
CCP: 4801, 4802, 4803, 4804, 4805, 481,
482, 483
OHIP fee: R741, R742, R743, G298,
E646, E651, E652, E654, E655, G262,
Z434, Z448
OHIP dx: 410, 412, 413
CIHI-DAD ICD-10: E1030, E1031, E1032, E1033,
E1130, E1131, E1132, E1133, E1330,
E1331, E1332, E1333, E1430, E1431,
E1432, E1433, H360
CIHI-DAD ICD-10: E1040, E1041, E1042, E1048,
E1049, E1440, E1441, E1442, E1448,
E1140, E1141, E1142, E1148, E1340,
E1341, E1342, E1348, E1349, G590,
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Peripheral vascular disease

Hypertension
Hypotension
Hypoglycemia
Hyperglycemic emergency
Hyponatremia
Influenza vaccination
Respiratory infection

Skin & soft tissue infection

Infections, other

Hyperkalemia
Urinary incontinence
Urinary retention
Urinary tract infections

Charlson comorbidity index

G632, G990
CIHI-DAD ICD-10: I700, I702, I708, I709, I731, I738,
I739, K551
OHIP
CCP: 5125, 5129, 5014, 5016, 5018, 5028,
5038, 5126, 5159
CCI: 1KA76, 1KA50, 1KE76, 1KG50,
1KG57, 1KG76MI, 1KG87, 1IA87LA,
1IB87LA, 1IC87LA, 1ID87, 1KA87LA,
1KE57
OHIP fee: R787, R780, R797, R804,
R809, R875, R815, R936, R783, R784,
R785, E626, R814, R786, R937, R860,
R861, R855, R856, R933, R934, R791,
E672, R794, R813, R867, E649
ODB
CIHI-DAD ICD-10: I95
CIHI-DAD ICD-10: E15, E160, E161, E162, E1063,
E1163, E1363, E1463
CIHI-DAD ICD-10: E1410, E1412, E1010, E1012,
E1110, E1112, E1300, E140
CIHI-DAD ICD-10: E871
OHIP
OHIP fee: G590, G591
CIHI-DAD ICD-10: 462, 5191, 5180, 5181, 5812,
51889, 5192, 5193, 5194, 5198, 5199,
OHIP
3821, 3822, 3823, 3824, 3829, 463, 4660,
485, 481, 514, 486, 4919, 4650, 4658,
4659, 4740, 4741, 4749, 4610, 4611, 4612,
4613, 4618, 4619, 496, 0340
ICD-10: J22, J02, J98, H66, J03, H65, J20,
J18, J42, J06, J35, J01, J44
OHIP dx: 519, 460, 382, 463, 381, 466,
486, 491, 474, 461, 496, 034
CIHI-DAD ICD-10: L08, L03, T01, L01, T814, A46
OHIP dx: 709, 686, 698, 682, 998, 879,
OHIP
894, 884, 684, 250
CIHI-DAD ICD-10: A49
OHIP dx: 786, 136, 040, 039
OHIP
CIHI-DAD ICD-10: E875
CIHI-DAD ICD-10: N393, N394, R32
CIHI-DAD ICD-10: R33
CIHI-DAD ICD-10: N10, N11, N12, n136, N151,
N159, N160, N300, N308, N309, N340,
N390, N410, N411, N412, N413, N431,
N45, T835
CIHI-DAD
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Healthcare Utilization
Number of any
hospitalizations
Number of any emergency
room visits
GP/FP visits

Cardiologist visits
Opthamologist vists
Endocrinologist vists
Nephrologist visits

Diabetes management
Diabetes incentive
Diabetes management by a
specialist
Diabetes management by a
specialist team
Cholesterol tests
Proteinuria
Serum creatine tests
Glucose tests
HbA1c tests
DVT/PE
Bone mineral density test

Hearing test

Sputum
Wound swab
Holter monitoring

Cardiac stress test

CIHI-DAD
NACRS
OHIP
IPDB
IPDB
IPDB
IPDB
OHIP
IPDB
OHIP
OHIP
OHIP

OHIP fee: K030
OHIP fee: Q040
OHIP fee: K045

OHIP

OHIP fee: K046

OHIP
OHIP
OHIP
OHIP
OHIP
CIHI-DAD
OHIP

OHIP fee: L055
OHIP fee: L253, L254, L255, G009, G010
OHIP fee: L065, L067, L068
OHIP fee: L104, L253, L103, L111
OHIP fee: L093
ICD-10: I26, I743, I801, I802, I803
OHIP fee: J654, J688, J854, J888, X149,
X152, X153, X155, Y654, Y688, Y854,
Y888
OHIP
OHIP fee: G153, G154, G440, G441,
G442, G443, G448, G450, G451, G452,
G525, G526, G529, G530, G533, G815,
G816
OHIP
OHIP fee: L629, L716, L815
OHIP
OHIP fee: L628
CIHI-DAD CCI: 2HZ24JAKH
OHIP fee: G311, G320, G647, G648,
OHIP
G649, G650, G651, G652, G653, G654,
G655, G656, G657, G658, G659, G660,
G661, G682, G683, G684, G685, G686,
G687, G688, G689, G690, G692, G693
CIHI-DAD CCP: 0341, 0342, 0343, 0344, 0605
CCI: 2HZ08, 3IP70
OHIP
OHIP fee: G315, G174, G111, G112,
G319, G582, G583, G584, J607, J608,
J807, J808, J809, J866, J609, J666
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Coronary revascularization

Electrocardiography

Pulmonary function test
At-home physician service

Urinalysis
Cystoscopy
Transurethral resection of
the prostate

Carotid ultrasound

Cardiac catheterization

Coronary angiogram

Electroencephalography
(EEG)
Chest x-ray
Echocardiography

CIHI-DAD CCP: 481, 482, 483, 480
CCI: 1IJ50, 1IJ26, IIJ27, 1IJ57, 1IJ76,
OHIP
1IJ57GQ, 1IJ54GQAZ
OHIP fee: R741, R742, R743, E651, E652,
E654, E646, G298, Z434, G262
CIHI-DAD CCI: 2HZ24JAKE
OHIP fee: G310, G313
OHIP
OHIP
OHIP fee: L354, L358
OHIP
OHIP fee: A901, B960, B961, B962,
B963, B964, B966, B990, B992, B993,
B994, B996, B997, B998
OHIP
OHIP Fee: L253, L254, L255, L633,
L634, L641, G009, G010
OHIP
OHIP fee: Z606, Z607, Z628, Z632, Z633,
Z634
CIHI-DAD CCI: 1QT59BAAD, 1QT59BAAG,
1QT59BAAW, 1QT59BAAZ,
OHIP
1QT59BACG, 1QT59BAGX, 1QT87BA,
1QT87BAAG, 1QT87BAAK
CCP: 721
OHIP fee: S655
CIHI-DAD CCP: 0281
CCI: 3JE30, 3JG30
OHIP
OHIP fee: J201, J501, J190, J191, J490,
J491, J492
CIHI-DAD CCP: 4995, 4996, 4997, 4892, 4893, 4894,
4895, 4896, 4897, 4898
OHIP
CCI: 3IJ30GP, 3HZ30GP, 2HZ24GPKJ,
2HZ24GPKL, 2HZ24GPKM,
2HZ24GPXJ, 2HZ28GPPL, 2HZ71GP,
3IP10, 3IS10
OHIP fee: G296, G297, G299, G300,
G301, G304, G305, G306, G297, G509
CIHI-DAD CCP: 4892, 4893, 4894, 4895, 4896, 4897,
4898
OHIP
CCI: 3IP10, 3IS10
OHIP fee: G297, G509
OHIP
OHIP fee: G414, G415, G416, G417,
G418, G540, G542, G544, G545, G546,
G554, G555
OHIP
OHIP fee: X090, X091, X092, X195
CIHI-DAD CCP: 0282
CCI: 3IP30
OHIP
OHIP fee: G560, G561, G562, G566,
G567, G568, G570, G571, G572, G574,
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Prostate-specific antigen
test
Cervical cancer screening
Laboratory Measurements
eGFR (using serum
creatinine)
Serum creatinine
Serum potassium
Albumin-to-creatinine ratio
Glycated hemoglobin

OHIP
OHIP

G575, G576, G577, G578, G581
OHIP fee: Q005, Q118, Q119, Q120,
Q121, Q122, Q123, Q133
OHIP fee: E430, G365, G394, L713, L812

OLIS
OLIS
OLIS
OLIS
OLIS

OLIS: 14682-9
OLIS: 2823-3, 6298-4,39789-3
OLIS: 14959-1, 30000-4, 32294-1
OLIS: 4548-4, 71875-9, 59261-8, 17855-8,
17856-6, 41995-2
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Appendix F. Variables included in the propensity score

Variables included in the propensity score
Age
Sex
Entry year
Demographics
Rural residence
Neighbourhood income quintile
Local Health Integration Network
Duration of diabetes
Acute kidney injury
Chronic kidney disease
Acute urinary retention
Chronic obstructive pulmonary disease
Chronic lung disease
Percutaneous coronary intervention
Pacemaker
Cancer
Stroke
Atrial fibrillation
Ventricular arrhythmia
Comorbidities
Coronary artery bypass graft surgery
Congestive heart failure
Chronic liver disease
Coronary artery disease
Diabetic retinopathy
Diabetic neuropathy
Peripheral vascular disease
Hypertension
Hypotension
Hypoglycemia
Hyponatremia
Hyperkalemia
Charlson comorbidity index
Angiotensin-converting enzyme inhibitors
Angiotensin receptor blockers
Acetylsalicyclic acid
Beta blockers
Calcium channel blockers
Medications
Loop diuretics
Potassium sparing diuretics
Nonsteroidal anti-inflammatory drugs
Statins
Thiazide diuretics
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Healthcare Utilization

Proton pump inhibitors
Picosalax
Insulin use 120 days prior to the cohort
entry date
Acarbose use 120 days prior to the cohort
entry date
Gliclazide use120 days prior to the cohort
entry date
Glyburide use 120 days prior to the cohort
entry date
Metformin use 120 days prior to the cohort
entry date
Pioglitazine use 120 days prior
Insulin use on the cohort entry date
Acarbose use on the cohort entry date
Gliclazide use on the cohort entry date
Glyburide use on the cohort entry date
Metformin use on the cohort entry date
Insulin use in the 1 year to 120 days prior to
the cohort entry date
Acarbose use in the 1 year to 120 days prior
to the cohort entry date
Gliclazide use in the 1 year to 120 days
prior to the cohort entry date
Glyburide use in the 1 year to 120 days prior
to the cohort entry date
Metformin use in the 1 year to 120 days
prior to the cohort entry date
Pioglitazine use in the 1 year to 120 days
prior to the cohort entry date
Number of any hospitalizations
Number of emergency department visits
Number of general practice or family
practice visits
Number of cardiologist visits
Number of opthamologist visits
Number of endocrinologist visits
Number of nephrologist visits
Diabetes management
Diabetes incentive
Diabetes management by a specialist
Diabetes management by a specialist team
Cholesterol test
Proteinuria
Serum creatinine test
Glucose test
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Other

Glycated hemoglobin test
Bone mineral density test
Hearing test
Holter monitoring
Cardiac stress test
Coronary revascularization
Electrocardiography
Pulmonary function test
At-home physician service
Urinalysis
Cystoscopy
Carotid ultrasound
Cardiac catheterization
Coronary angiogram
Electroencephalography
Chest x-ray
Echocardiography
Prostate-specific antigen test
Cervical cancer screening
Prescribing physician specialty
Number of medications
Estimated baseline glomerular filtration rate
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Appendix G. 2012 KDIGO thresholds for AKI stages (27)

Stage
1
2
3

Definition
50 to <100% increase in serum creatinine from baseline or an absolute
increase ≥0.3 mg/dL, but does not meet stage two or three criteria
100 to <200% increase from baseline
≥200% increase from baseline, absolute serum creatinine value of 4.0
mg/dL, or receipt of acute dialysis
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Appendix H. ACE inhibitors, ARBs and all type of diuretic drugs included in the
subgroup analysis

Drug Name
ACE inhibitor
Captopril

Lisinopril

Enalapril sodium

Benazepril chlorohydrate
Cilazapril

Quinapril
Ramipril

Drug Identification Numbers
00546283, 00546291, 00546305, 00695661, 00851639, 00851647,
00851655, 00851833, 00893595, 00893609, 00893617, 00893625,
01913824, 01913832, 01913840, 01913859, 01942964, 01942972,
01942980, 01942999, 02163551, 02163578, 02163586, 02163594,
02230203, 02230204, 02230205, 02230206, 02237861, 02237862,
02237863, 02242788, 02242789, 02242790, 02242791
00839329, 00839337, 00839388, 00839396, 00839418, 00839442,
02049333, 02049376, 02049384, 02217481, 02217503, 02217511,
02256797, 02256800, 02256819, 02271443, 02271451, 02271478,
02274833, 02274841, 02274868, 02285061, 02285088, 02285096,
02285118, 02285126, 02285134, 02289199, 02289202, 02289229,
02292203, 02292211, 02292238, 02294230, 02294249, 02294257,
02294591, 02299879, 02299887, 02299895, 02332167, 02332175,
02332183, 02361531, 02361558, 02361566, 02394472, 02394480,
02394499, 09853685, 09853960, 09854010, 09857272, 09857286,
09857287
00670901, 00670928, 00708879, 00708887, 00851795, 02019884,
02019892, 02019906, 02020025, 02233005, 02233006, 02233007,
02291878, 02291886, 02291894, 02291908, 02299933, 02299941,
02299968, 02299976, 02299984, 02299992, 02300001, 02300028,
02300036, 02300044, 02300052, 02300060, 02300079, 02300087,
02300095, 02300109, 02300117, 02300125, 02300133, 02300141,
02300680, 02352230, 02352249, 02352257, 02352265
00885835, 00885843, 00885851
01911465, 01911473, 01911481, 02266350, 02266369, 02266377,
02280442, 02280450, 02280469, 02283778, 02283786, 02283794,
02285215, 02285223, 02291134, 02291142, 02291150
01947664, 01947672, 01947680, 01947699, 02248499, 02248500,
02248501, 02248502, 02290987, 02290995, 02291002, 02291010
02050943, 02050951, 02050978, 02050986, 02221829, 02221837,
02221845, 02221853, 02247917, 02247918, 02247919, 02247945,
02247946, 02247947, 02251515, 02251531, 02251574, 02251582,
02255316, 02255324, 02255332, 02283891, 02287692, 02287706,
02287714, 02287722, 02287927, 02287935, 02287943, 02291398,
02291401, 02291428, 02291436, 02295369, 02295482, 02295490,
02295504, 02295512, 02299372, 02301148, 02301156, 02301164,
02301172, 02310503, 02310511, 02310538, 02310546, 02331101,
02331128, 02331136, 02331144, 02332299, 02332302, 02332310,
02332329, 02374846, 02374854, 02374862, 02387387, 02387395,
02387409, 02387417, 02420457, 02420465, 02420473, 02420481,
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Perindopril tertbutylamine
Trandolapril
Fosinopril
Fosinopril sodium

Benazapril HCL
Hydrochlorothiazide &
Lisinopril
ARB
Losartan potassium

Valsartan

Irbesartan

Candesartan Cilexetil

Eprosartan Mesylate
Telmisartan

Eprosartan Mesylate &
Hydrochlorothiazide
Olmesartan Medoxomil

02421305, 02421313, 02421321, 02438860, 02438879, 02438887,
02438895
02123274, 02123282, 02246624
02231459, 02231460, 02239267
02242733, 02242734, 02262401, 02262428, 02331004, 02331012
02247802, 02247803, 02255944, 02255952, 02266008, 02266016,
02275252, 02275260, 02294524, 02294532, 02332566, 02332574,
01907107, 01907115
02273918, 02290332, 02290340
02301768

02182815, 02182874, 02182882, 02309750, 02309769, 02309777,
02313332, 02313340, 02313359, 02353504, 02353512, 02354829,
02354837, 02354845, 02357968, 02357976, 02368277, 02368285,
02368293, 02379058, 02380838, 02398834, 02398842, 02398850,
02403323, 02403331, 02403358, 02404451, 02404478, 02404486,
02405733, 02405741, 02405768, 02422468, 02422484, 02424967,
02424975, 02424983, 02426595, 02426609, 02426617
02236808, 02236809, 02244781, 02244782, 02289504, 02313006,
02313014, 02337495, 02337509, 02337517, 02344564, 02356651,
02356678, 02356686, 02356759, 02356767, 02356775, 02363100,
02363119, 02371529, 02371537, 02371545, 02383535, 02383543,
02383551, 02414228, 02414236, 02414244
02237923, 02237924, 02237925, 02315971, 02315998, 02316005,
02316390, 02316404, 02316412, 02317060, 02317079, 02317087,
02328070, 02328089, 02328100, 02328461, 02328488, 02328496,
02347296, 02347318, 02347326, 02386968, 02386976, 02386984,
02406810, 02406829, 02406837, 02418193, 02418207, 02418215,
02422980, 02422999, 02423006, 02427087, 02427095, 02427109
02239090, 02239091, 02239092, 02311658, 02326957, 02326965,
02326973, 02365340, 02365359, 02365367, 02366312, 02366320,
02366339, 02376520, 02376539, 02376547, 02376555, 02379120,
02379139, 02379147, 02379155, 02379260, 02379279, 02379287,
02379295, 02380684, 02380692, 02380706, 02380714, 02386496,
02386518, 02386526, 02386534, 02391171, 02391198, 02391201,
02391228, 02392267, 02399105, 02417340
02240431, 02240432, 02243942
02240769, 02240770, 02320177, 02320185, 02375958, 02375966,
02376717, 02376725, 02391236, 02391244, 02393247, 02393255,
02407485, 02407493, 02420082, 02420090, 02432897, 02432900,
02434164
02253631
02318660, 02318679

87

Hydrochlorothiazide &
Quinopril
Hydrochlorothiazide &
Telmisartan
Loop Diuretics
Bumetanide
Ethacrynic acid
Furosemide

02408775
02433214

00728276, 00728284, 02176076
00016497, 02258528
00012580, 00217743, 00289590, 00332275, 00337730, 00337749,
00344079, 00353612, 00362166, 00380016, 00380024, 00396249,
00396788, 00432342, 00527033, 01900943, 01987585, 01987615,
01987739, 01987798, 01988832, 02224690, 02224704, 02224720,
02224755, 09857208
Potassium Sparring Diuretics
Amiloride HCL
00487805, 02249510
Amiloride HCL &
00487813, 00784400, 00886106, 01937219, 02174596, 02257378
Hydrochlorothiazide
Eplerenone
02323052, 02323060
Hydrochlorothiazide &
00180408, 00594377, 00613231, 00657182
Spironolactone
Hydrochlorothiazide &
00509353
Trimolol Maleate
Hydrochlorothiazide &
00181528, 00441775, 00532657, 00865532, 01910191, 01919547
Triamterene
Spironolactone
00028606, 00285455, 00613215, 00613223
Triamterene
00027138, 00299715, 01919563, 01919571
Thiazide Diuretics
Chlorthalidone
00010413, 00010421, 00293881, 00298964, 00337447, 00337455,
00360279, 00360287, 00398365, 00398373
Hydrochlorothiazide
00016500, 00016519, 00021474, 00021482, 00092681, 00092703,
00263907, 00312800, 00326844, 02247386, 02247387
Indapamide
00564966, 02049341, 02153483, 02179709, 02223597, 02223678,
02227339, 02231184, 02239619, 02239620, 02240067, 02245246,
02373904, 02373912
Metolazone
00301663, 00301671, 00301698, 00888400, 00888419, 00888427
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Appendix I. Serum creatinine measurement during the follow-up period

Observed
No. events (%)
SGLT2
DPP4
inhibitors
inhibitors
(n=19,611)
(n=19,483)
At least one
serum
creatinine
measurement c

10,619 (54.15)

9,602 (49.28)

Weightedb
No. events (%)
SGLT2
DPP4
inhibitors
inhibitors
(n=19,611)
(n=19,775)
10,619
(54.15)

9,718
(49.14)

Risk difference, %
(95% CI)

Risk Ratio
(95% CI)

P
value

5.00
(3.65 to 6.36)

1.10
(1.07 to 1.13)

< 0.01

Abbreviations: CI= confidence interval, DPP4= dipeptidyl peptidase-4, SGLT2= sodium-glucose cotransporter-2
aReference group: DPP4 inhibitor users.
b Weighted using inverse probability of treatment weighting based on propensity scores, using weights to estimate the average
treatment effect in the treated. Patients in the reference group were weighted as [propensity score/(1 - propensity score)]. This method
produces a weighted pseudo-sample of patients in the reference group with the same distribution of measured covariates as the
exposure group (71,73,74). Weighted relative risks and 95% CIs were obtained using modified Poisson regression (88) and weighted
risk differences and 95% CIs were obtained using a binomial regression model with an identity link function.
cBased on tests done in an outpatient setting assessed using the Ontario Laboratories Information System serum creatinine values.
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Appendix J. Absolute changes (µmol/L) in serum creatinine after SGLT2 inhibitor and DPP4 inhibitor initiation

DPP4i users

SGLT2i users
N
10,936

Unit change (weighted)
Mean (SD) 95% CI Median
(IQR)
8 (26)
7-8
5 (-1,12)

N
10,070

Weighted mean difference
Estimate
95% CI
1 .01
0.30-1.71
aWeighted

Unit change (weighted)
Mean (SD) 95% CI Median
(IQR)
7 (26)
6-7
4 (-2,11)

pvalue
0.005

mean difference and 95% CIs were obtained using a normal regression model with an identity link function.
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Appendix K. Percent changes in serum creatinine after SGLT2 inhibitor and DPP4 inhibitor initiation

DPP4i users

SGLT2i users
N
10,936

Unit change (weighted)
Mean (SD)
95% CI
Median
(IQR)
10 (32)
9-11
7 (-1,16)

N
10,070

Weighted mean difference
Estimate
95% CI
1.27
aWeighted

0.45-2.10

Unit change (weighted)
Mean (SD) 95% CI Median
(IQR)
9 (29)
8-9
5 (-3,14)

pvalue
0.002

mean difference and 95% CIs were obtained using a normal regression model with an identity link function.
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Appendix L. Risk of hospital encounter with acute kidney injurya within 365 days among SGLT2 inhibitor new users compared with
DPP4 inhibitor new users

Observed
No.
patients
SGLT2
inhibitors

19,611

DPP4 inhibitorsb

19,483

No.
events
(%)
2,666
(13.59)
3,712
(19.05)

Event rate
per 1000
personyears

No.
patients

172.42

19,611

245.77

19,775

No. events
(%)
2,666
(13.59)
3,164
(16.00)

Weightedc
Event rate
per 1000
personyears
172.42
207.51

Hazard ratio
(95% CI)

P
value

0.83 (0.78 to
0.89)d

<.0001

Abbreviations: CI= confidence interval, DPP4= dipeptidyl peptidase-4, SGLT2= sodium-glucose cotransporter-2
a365- day risk of acute kidney injury, based on hospital presentation (emergency department or hospitalization) assessed using the
Ontario Laboratories Information System serum creatinine values.
b Reference group: DPP4 inhibitor users.
cWeighted using inverse probability of treatment weighting based on propensity scores, using weights to estimate the average
treatment effect in the treated. Patients in the reference group were weighted as [propensity score/(1 - propensity score)]. This method
produces a weighted pseudo-sample of patients in the reference group with the same distribution of measured covariates as the
exposure group (71,73,74).
d Weighted hazard ratio and 95% CI were obtained using Cox regression (with 365-day follow-up censoring on death). A similar result
was observed when death was treated as a competing risk. 95% CI was obtained using a bootstrap estimator (100). In addition, the
proportional hazards assumption was tested by including time dependent covariates in the model and the assumption was not violated.
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Appendix M. 90-day risk of hospital encounter with bowel obstruction

Outcome
Bowel
obstructionc

Observed
No. events (%)
SGLT2
inhibitors
(n=19,611)

DPP4
inhibitors
(n=19,483)

Weightedb
No. events (%)
SGLT2
DPP4
inhibitors
inhibitors
(n=19,611) (n=19,775)

20 (0.10)

36 (0.18)

20 (0.10)

20 (0.10)

Risk difference,
%
(95% CI)

P
value

0 (-0.07 to 0.07)

1.00

Risk ratio
(95% CI)

1.00 (0.49 to
2.06)

P
value

1.00

Abbreviations: CI= confidence interval, DPP4= dipeptidyl peptidase-4, SGLT2= sodium-glucose cotransporter-2.
aReference group: DPP4 inhibitor users.
b Weighted using inverse probability of treatment weighting based on propensity scores, using weights to estimate the average
treatment effect in the treated. Patients in the reference group were weighted as [propensity score/(1 - propensity score)]. This method
produces a weighted pseudo-sample of patients in the reference group with the same distribution of measured covariates as the
exposure group (71,73,74). Weighted risk ratios and 95% CIs were obtained using modified Poisson regression (88) and weighted risk
differences and 95% CIs were obtained using a binomial regression model with an identity link function.
cBased on hospital presentation (emergency department or hospitalization) assessed using diagnostic codes.
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Appendix N. Post-hoc E-value analysis

E-value for point estimate: 1.83 and for confidence interval: 1.14
Each point along the curve defines a joint relationship between the two sensitivity
parameters that could potentially explain away the estimated effect. If one of the two
parameters is smaller than the E-value, the other must be larger, as defined by the plotted
curve
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